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ABSTRACT
Non-Ribosomal Peptide Synthetases (NRPSs) and their exogenous
tailoring partners have been heavily studied but not in the context of non-cognate
systems. Orf78, a dinuclear iron β-hydroxylase from the lysobacter pathway and
homologous to CmlA from the chloramphenicol pathway, is used to test affinities
for one native and two non-native T-domains. Results indicate that there is
enough difference between Type I and Type II NRPS systems to disfavor
common recognition motifs. Additionally, the β-hydroxylase P450sky, from the
skyllamycin biosynthetic pathway, is used in conjunction with the NRPS ATdomain NikP1AT from the nikkomycin biosynthetic pathway, in lieu of the
homolog P450nikQ. The second portion of the thesis will discuss the creation of
a sustainable source of biodiesel products are currently a goal of ‘green’
programs. The fatty acid decarboxylase P450olet uses the cheaply obtainable
hydrogen peroxide as the oxidant to achieve a high-valent iron species.
Substitution of the iron for manganese in the porphyrin scaffold raises the redox
potential and forms a Mn(IV)-oxo complex that is too weak to perform C-H bond
abstractions. Alternatively, substitution of the iron-protoporphyrin IX with ironmesoporphyrin IX lowers the redox potential, increasing the amount of
hydroxylated fatty acid at lower carbon chain lengths but also leads to a
decrease in the efficiency in multiple turnover reactions.
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CHAPTER 1
A COMPARISON OF PCP DOMAINS AND THEIR RECOGNITION WITH A
DINUCLEAR IRON HYDROXYLASE FROM THE LYSOBACTIN BIOSYNTHETIC
PATHWAY
1.1 INTRODUCTION
The necessity to diversify the antibiotic arsenal has never been as crucial as it is
now with the current level of antibiotic resistant bacteria causing problematic
issues in the realm of public health, particularly Streptococcal and
Staphylococcal species 1-3. Although attempts are currently being pursued
through synthetic means 4-6, the production of more complex antibiotics may be
cost-prohibitive, if not synthetically unachievable. One potentially viable route is
through modification of the antibiotic machinery, known as non-ribosomal peptide
synthetases (NRPS). Such efforts may create opportunities to synthesize a
library of compounds built around a structural scaffold that can be subsequently
screened for antimicrobial activity. Specifically, the use of a pre-existing NRPS
complex, a protein megastructure that produces peptide-based antibiotics
through an assembly-line process, may provide a useful tool for the incorporation
of non-cognate tailoring enzymes as a means for producing modified versions of
current antibiotics. This method has not gained widespread popularity due to its
trial-and-error approach and its typically low-yields of product 7. Alternatively,
1

entire operons have been transplanted from one organism to another with
successful production of antibiotic. Although providing new biological platforms
for synthesis, pathogenic bacteria may have already developed resistance to
these natural products 8. There has been very little research involving the
transplantation of enzymes from one antibiotic biosynthetic pathway to another to
generate new products. Homologous enzymes must be identified and
characterized to determine their suitability for a non-ribosomal peptide
synthetase (NRPS) system that is not natively recognized.
Reviews by Marahiel group give an in-depth explanations of how an
NRPS is formed and how they function to create an antibiotic product 9, 10.
Briefly, a NRPS is a modular complex with each module involved with the
identification and activation of a particular amino acid that ultimately becomes
incorporated into a nascent peptide chain. These modules are further divided
into individual domains which are each responsible for a specific aspect of the
identification, modification, and transfer of the amino acid into the nascent
peptide chain. In a canonical multimodular NRPS system, a single module
contains three domains: the Adenylation (A) domain identifies and activates a
specific amino acid through an adenylation reaction, the Thiolation (T or PCP)
domain tethers the activated amino acid through a thioester bond onto a posttranslationally transferred phosphopanthetheine (ppant) and transports the
substrate between domains, and the Condensation (C) domain which extends
the nascent polypeptide chain. One interesting deviation from this operation that
will be discussed here is the modification of the tethered substrate by enzymes
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that operate in trans to the NRPS, such as the β-hydroxylases CmlA and
P450 sky , providing a method to diversify the final product.
The recognition event may depend on either ionic or hydrophobic binding
domains present on the surfaces of the enzyme and the T-domain, enzyme
specificity for the tethered amino acid, or a combination of both. P450
hydroxylases that operate in this fashion, such as P450 NikQ and P450 sky , are
reported to rely on hydrophobic interactions to properly recognize the binding
motif of the NRPS, although these residues have yet to be fully elucidated 11, 12.
However, there is potential for greater product diversity if these binding motifs
can be solved and incorporated into modules of an NRPS that incorporate nonmodified amino acids, allowing for the creation of modified products. The βhydroxylase Orf78, associated with the lysobactin biosynthetic pathway, is
homologous with CmlA from the chloramphenicol biosynthetic pathway.
However, the uniqueness of Orf78 lies with its ability to recognize and
hydroxylate substrate attached to three individual NRPS modules instead of the
singular modification conducted by CmlA. Study of the similarities and
recognition flexibilities between the hydroxylase binding motifs will be conducted
through comparisons of interactions between Orf78 and native and non-native Tdomains and gathering information necessary to successfully modify an NRPS
pathway to create a familiar but unique antibiotic-like compound.
Lysobactin is a depsipeptide-based antibiotic isolated from Lysobacter sp.
SC 14067 (ATCC 53042) 13, 14 (Figure 1.1, bottom). In its biologically active form,
it binds to the D-Ala-D-Ala unit of Lipid II during the bacterial biosynthesis of
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peptidoglycan and inhibits the synthesis of new cell wall in gram-positive bacteria
15

. The inability for the bacteria to synthesize a new cell wall decreases its

overall robustness, allowing turgor pressure to weaken the cell from within and
ruptures in the cell membrane. This mechanism of bacteriocide places
lysobactin in the same category as vancomycin 16 and similar derivatives, such
as teixobactin 17 and balhimycin 18. However, the importance of lysobactin lies in
in the fact that its minimum inhibitory concentration is one quarter of
vancomycin’s on gram-positive bacteria 13, with its strength leading to lower
dosages and the hope of a prolonged lifetime prior to eventual ineffectiveness
due to the evolution of antibiotic-resistant strains of gram-positive bacteria. Due
to the inhibitory effects of the drug to Lipid II, there is no activity towards
mammalian cells, making the drug a possible candidate for use against
troublesome gram-positive bacteria common in hospitals, such as
Staphylococcus aureus and Streptococcus pneumoniae.
The lysobactin NRPS biosynthesis pathway is organized into eleven
modules segregated into two genes, with hydroxylation of two modules on LybA
associated with hydrophobic substrates (Phe3 and Leu4) and one module on
LybB associated with a weakly acidic substrate (Asn10) 19 (Figure 1.1, top). This
contrasts with CmlA, which solely hydroxylates the hydrophobic non-native
amino acid L-para-aminobenzoic acid (L-PABA) 20. This also differs from
P450 sky , a hydroxylase with a heme cofactor that hydroxylates three modules on
the skyllamycin biosynthetic pathway associated with three hydrophobic
substrates (PCP Phe5 , PCP Tyr7 , and PCP Leu11 ) 21. For Orf78, the diversity of
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recognized charges on the substrate side-chain may allow for greater flexibility
for recognition than with other β-hydroxylases; however, the reasons why some
amino acids are hydroxylated while others are not is unclear. The structure of
the antibiotic shows the β-hydroxyl group on PCP Phe3 is necessary to form an
intermolecular lactone with the C-terminal carboxylate of the nascent peptide
chain. However, it is unknown what functions the β-OH groups on PCP Leu4 and
PCP Asn10 serve, except at the very least assisting to solubilize the active
compound, which is mostly hydrophobic in nature.
Makris et al. showed that oxidation kinetics on Type I NRPS systems
(CmlA/CmlP AT ) can be used as an indirect measurement to determine binding of
the substrate carrier to the hydroxylase, with quicker rates indicative of greater
oxygen access to the active site of the enzyme 20. For heme-bound
hydroxylases, the dissociation constants with Type II NRPS systems
(P450 sky /PCP7 O-Me-Tyr ) 12, 20 were used to show the differences between bound
and unbound substrate carriers. However, there is no information concerning
cross-recognition for a Type II-associated hydroxylase with non-native Type I or
II NRPS systems. Following basic characterization of Orf78, to include iron
quantitation and structural features, a comparative analysis of oxidation kinetics
between Orf78 and modular components from three different systems will be
performed, utilizing the following T-domains: PCP Asn10 from the lysobactin
system, CmlP T from the chloramphenicol system, and PCP Phe6 from the
teichoplanin system.
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1.2 MATERIALS AND METHODS
Cloning
The orf78 gene was cloned from the genomic template from Lysobacter
sp. 53042 (ATCC). The following primers were utilized for the amplification of the
orf78 gene with Taq polymerase (NEB), where the capitalized regions are the
restriction sites for SfaAI and MssI:
forward - 5’-ccatatgGCGATCGCcaataccactca-3’
reverse - 5’-ccatatgGTTTAAACtcacagaagcag-3’
The amplicon and pVP91A vector were both digested with SfaAI and MssI
(Thermo Fisher Scientific), gel-purified, and ligated with T4 DNA ligase (NEB).
The insert was verified using the facilities at ACGT, Inc.
The PCP Asn10 gene was similarly cloned from the genomic template of
Lysobacter sp. 53042 (ATCC). The following primers were utilized for the
amplification of the A10T gene with Q5 polymerase (NEB), where the capitalized
regions are the restriction sites EcoRI and HindIII:
forward - 5'- cgtatcCATATGctgctgtcgccgccgcagcgcgag -3'
reverse - 5'- cgtatcAAGCTTcgccggcaacgccgccccgc -3'
The amplicon and pET21b(+) vector were both digested with EcoRI and HindIII
(NEB), gel-purified, and ligated with T4 DNA ligase (NEB). The sequence was
verified using the facilities at ACGT, Inc.
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Protein Expression and Purification
The Orf78 plasmid was chemically transformed into BL21(Dε3) cells. A
single colony was used to inoculate a starter culture which were used as
inoculant for 1 liter flasks of M9 minimal media. The components of the M9
minimal media consists of: 200 mL M9 salts, 2 mL of 1 M MgSO 4 , 20 mL of 20%
glucose, 100 µL of 1 M CaCl 2 , 12 mL overnight culture, and 1 mL of 100 mg/mL
Ampicillin. The culture was induced at an OD 600 =0.7 with the addition of 150 µM
isopropyl β-D-1-thiogalactopyranoside (IPTG; RPI corp.) supplemented with 50
µM FeCl 3 with further incubation for 16 hours at 18oC. The cells were lysed,
cleared, and purified with Ni-NTA resin equilibrated with 50 mM sodium
phosphate, monobasic, 300 mM sodium chloride, pH=7.5, 10 mM imidazole
(Buffer A), washed with Buffer A + 10 mM imidazole, and eluted with Buffer
A+240 mM imidazole. Following purification, the eluent was dialyzed overnight in
50 mM HEPES, pH=7.5 + 10% glycerol. The protein was concentrated,
aliquoted, and stored at -80oC.
The PCP Asn10 plasmid was chemically transformed into BL21(Dε3) cells.
A single colony was used to inoculate a starter culture which were used as
inoculant for 1 liter flasks of Luria-Bertani media. The culture was induced at
OD 600 =0.6 with 150 µM IPTG followed by incubation for an additional 16 hours at
37oC. The cells were lysed, cleared, and purified with Ni-NTA column
equilibrated with Buffer A, washed with Buffer A + 10 mM imidazole, and eluted
with Buffer A + 240 mM imidazole followed by dialysis overnight in 25 mM
HEPES, pH=7.5. The dialysate was subsequently loaded onto DEAE resin
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equilibrated with 25 mM HEPES, pH=7.5. The flow-through, which contains the
properly-folded protein, was dialyzed in 100 mM HEPES, pH=7.5, 30% glycerol
prior to concentrating, aliquoting, and storage at -80oC.
Size Exclusion Chromatography
Nine milligrams of Orf78 were loaded onto an S-200 size-exclusion
column attached to an ATKA FPLC equilibrated with 50 mM HEPES, pH=7.5 and
eluted at 0.3 mL/min. The elution profile was matched with a set of protein
standards with known molecular weight to determine the oligomeric state of the
enzyme.
UV-Vis
All UV-Vis measurements were obtained on an Agilent 8453 UV-Vis
spectrophotometer and analyzed on Agilent proprietary software or the OriginPro
software package. The concentration of Orf78 was calculated using Beer’s Law
and the theoretical ε 280 = 58.8 mM-1cm-1. An azide assay was used to determine
the presence of any diiron cluster within the enzyme. 50 µM of Orf78 was
incubated in 1 mL of 50 mM HEPES, pH=7.5, 8 M sodium azide for 20 minutes at
4oC. The solution was cleared by centrifugation at 4oC and spectrum taken of
the supernatant at 340 nm and 420 nm.
A reductive titration was performed to determine the number of electrons
necessary to fully reduce the enzyme from the fully oxidized state. All solutions
were buffered in 50 mM HEPES, pH=7.5 degassed with N 2 . A 2 mM solution of
sodium dithionite was utilized as a reductant. Separately, a solution of 50 uM
Orf78 was prepared in an anaerobic cuvette with the addition of 0.5 molar
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equivalents of methyl viologen. Sodium dithionite was titrated with a gas-tight
syringe in 30 µM increments until the charge-transfer band at 340 nm completely
bleached and the methyl viologen absorption peaks from 350-395 nm became
apparent, indicating full reduction of the enzyme. The data was analyzed on
OriginPro 2016 as a plot showing number of electrons against total absorbance
at 340 nm.
Electron Paramagnetic Resonance (EPR)
Spectra of the mixed-valent enzyme were collected on an EMXplus Xband EPR (Bruker) at 10K with 5 mW power and a microwave frequency of 9.834
GHz. Each spectrum is a composite of 15 averaged scans per sample. The
data were collected and analyzed on either the Bruker Xenon software suite or
the SpinCount software package. Determination of the g-values were performed
by the use of the equation g = (71.4484v) / B, where magnetic field, B (mT) and
the microwave frequency, v (GHz). All solutions were buffered in 50 mM
HEPES, pH=7.5 and degassed with N 2 . Sample preparation was performed
anaerobically with O 2 levels less than 1 ppm.
The visualization of the mixed-valent species involved the preparation of
four samples. The sample containing one electron-equivalent to create the
mixed-valent species involved the addition of 250 µM sodium dithionite to 400 µL
of 400 µM degassed Orf78 + 200 µM methyl viologen and incubated until the
solution transformed from purple to clear. The solution was transferred to a
quartz cuvette, capped, and frozen in liquid nitrogen for storage. For the
formation of the partial mixed-valent species by the addition of 0.8 electron-
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equivalents, 200 µM of sodium dithionite was added to 400 µM Orf78 + 200 µM
methyl viologen and stored as above. For samples containing no mixed-valent
species from 0.4 electron-equivalents, 400 µM Orf78 + 200 µM methyl viologen
were immediately frozen and stored. For samples containing no mixed-valent
species from two electron equivalents, 400 µM sodium dithionite was added to
400 µM Orf78 + 200 µM methyl viologen and frozen off for storage.
Alteration of the temperature can determine the protonation state of the
oxygen bridge between the two iron molecules. The mixed-valent species from
the fully mixed-valent sample above was measured at a constant power of 5 mW
and all spectra are an average of 15 scans. Measurements were taken at
temperature points at 4K, 16K, 25K, and 39K.
The sample with highest content of the mixed-valent form was
subsequently used for the power saturation experiment. The temperature was
kept at a constant temperature of 8K ± 0.75K and the power was increased from
0.07942 mW to 158.9 mW, with each spectrum representing the average of 15
scans. The distance, from peak to trough, of the second g-value was used as a
measure of the signal intensity (I) at any given power. The power at halfsaturation (P 1/2 ) was determined using the following equation:
I = I o *P 1/2 /(1+P/P 1/2 ))b/2
, where I o is the intensity under unsaturated conditions and b is a homogeneity
value assumed to be equal to 1. The data was plotted as log(I/√(P)) as a
function of power (mW).
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Synthesis of Coenzyme-A derivatives
Bodipy-CoA was synthesized by dissolving 110 nanograms each of
Bodipy-FL (Life Technologies) and Coenzyme A (CoA; RPI corp.) in 300 µL
DMSO + 1.8 mL 75 mM MES, pH=6 + 100 mM magnesium acetate. The solution
incubated on ice in a dark environment for 10 minutes followed by incubation at
room temperature in a dark environment for 2 hours while rapidly stirring. Pure
product was isolated with several extractions of ice-cold diethyl ether. Excess
ether was evaporated under N 2 prior to aliquoting and storage at -20oC.
Synthesis of Phe-CoA involved dissolving 5 mg of Boc-Amino Acid (AA), 4
mg dicyclohexylcarbodiimide (DCC, Sigma Aldrich), and 3 mg Nhydroxysuccinimide (NHS, Sigma Aldrich) with 1 mL acetonitrile and incubating
on ice for 10 minutes prior to stirring at room temperature for 24 hours under a
nitrogen atmosphere. Following the incubation time, 15 mg of CoA dissolved in
1.5 mL of 40 mM lithium carbonate were added to the solution and incubated on
ice for 5 minutes prior to further incubation at room temperature for an additional
2 hours. The addition of H 2 O:TIPS:TFA at a ratio of 2.5:2.5:95 was added to
deprotect the amine group of the Boc-AA-CoA and the solution was allowed to
stir at room temperature for 2 additional hours. The Phe-CoA was purified by
several extraction steps with ice-cold diethyl ether, resulting in the precipitation of
the desired product. The precipitated product was isolated via centrifugation,
dried under N 2 , and resuspended in dH 2 O to a concentration of 2.5 mM,
aliquoted, and stored at -20oC.
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SfP recognition of the T-domain
The Phe-PPant is transferred to the T-domain with a 4´phosphopantetheinyl transferase (SfP) derived from Bacillus subtilis and
expressed in E. coli. After the T-domain is purified, Bodipy-PPant is transferred
to test for SfP recognition of the serine residue, as part of the GGxS motif. The
reaction is set up with 30 mM magnesium chloride, 60 mM Tris, pH=8.0, 700 mM
AA-CoA, 5 µM SfP, and 200 µM apo-PCP Asn10 followed by incubation at room
temperature for 1 hour and desalting in 50 mM HEPES, pH=7.5. The sample is
then run on a 12% SDS-PAGE gel and, upon completion, viewed under a
transilluminator to verify its presence at ~10kDa. If the SfP recognizes the Tdomain, then the same procedure is used to transfer Phe-PPant for use in
Stopped-flow experiments.
Stopped-flow
Binding between Orf78 and any T-domain was determined by the rate of
rebound for the iron-oxo charge-transfer band at 340 nm from the bleached
reduced state to its re-emergence when oxidized. The measurement of the
oxidation rates for the hydroxylase/NRPS complex was performed on an SX20
Stopped-flow spectrophotometer (Applied Photophysics) for accurate
visualization and rate measurements. The temperature of the experiment was
set to 4oC and data was collected utilizing a PMT detector set at 340nm with
5000 time points over 500 seconds per measurement.
Syringe A contained 50 µM Orf78 + 25 µM methyl viologen that was fully
reduced with excess dithionite in an anaerobic bag and desalted to remove any
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small molecules. The solution was then transported anaerobically and loaded
into the stopped-flow pre-chilled at 4oC. Syringe B contained 50 mM HEPES, 2
mM O 2 , and one of the following: apo- PCP Asn10 , holo- PCP Asn10 , Phe-PCP Asn10 ,
Phe-CmlPAT from the chloramphenicol NRPS, or Phe-PCP Tyr6 from the
teichoplanin NRPS. The collected data was an average of triplicate traces for
each sample and fit to single exponential functions to determine the final rates in
Pro-Data Viewer (Applied Photophysics).

1.3 RESULTS
Orf78 contains a dinuclear iron cluster
An analysis of the sequence alignment shows the endogenous ligands
present in CmlA are fully conserved in Orf78 (Figure 1.2). A model of Orf78,
created using SWISS-MODEL 22 and the published structure of CmlA (PDBID:
4JO0) as a template, putatively confirms an overlap for all residues involved in
the ligation of the metal atoms. The first coordination sphere consists of three
His, two Glu, and two Asp residues, with one of the Asp forming a µ-1,1
carboxylate bridge between the two irons in the cluster. The presence of a
carboxylate bridge is not uncommon, but the bridge is not usually a µ-1,1
configuration, but rather a µ-1,3 carboxylate linkage. Crystallographic studies of
other diiron enzymes show at least one µ-1,3 carboxylate bridge, such as the
case with Methane Monooxygenase (MMO), Purple Acid Phosphatase (PAP),
and Ribonucleotide Reductase (RNR) 23-25. Specifically, the crystal structure of
CmlA confirms the presence of residue D403 forming a μ-1,1-carboxylate bridge
between the active site irons. However, the structure also shows the presence of
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an adventitious acetate anion present from the mother-liquor that may be
displacing D403 into a conformation forming a mono-dentate rather than bidentate bridge. It is worth noting that this same acetate anion may be
responsible for displacing residue D430, which is a viable ligand in range of an
iron atom. However, it is unknown whether a similar bridge or solvent ligation
pattern is present in Orf78, as attempts to crystallize the protein have been futile.
In similar fashion to that proposed for CmlA, Orf78 purifies as a dimer with
two joined 60.8 kDa units (Figure 1.3). Size-Exclusion Chromatography shows
the protein elution at around 125 kDa with no peaks associated with monomeric
or other oligomeric forms of the enzyme. The crystal structure for CmlA suggests
the dimer interaction is derived from a dimerization arm that electrostatically
interacts with the same domain on the opposing monomer in a hook-like fashion
separate from the active site region of the jelly-roll motif. Similar residues are
present at the dimer interface of the model for Orf78, inferring the nature of the
dimerization is electrostatic in nature as well.
Iron quantitation with the ferrozine assay consistently yields 1.7-2.3 irons
per dimer. These results were confirmed with ICP-MS and show only trace
amounts of manganese, zinc, and copper present in the sample. However, the
fully-loaded metal count for the dimer should be around four irons per dimer
since each active site in the dimer requires occupancy by two iron molecules.
Given the minimal media growth conditions supplemented with ample iron (III)
chloride, it is not known why complete loading does not occur. Metal
reconstitution experiments in both aerobic and anaerobic conditions have also
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been unsuccessful. Nonetheless, the lack of an appreciable high-spin Fe3+
signal in the as-isolated enzyme, reductive titration of Orf78 with sodium
dithionite, and the presence of a mixed-valent signal in EPR demonstrates that
almost all of the irons are bound as a cluster.
The UV-Vis spectrum of Orf78 consist of a broad spectral region with
weak extinction coefficients extending from 300-450 nm, culminating in a major
peak maximum at 340 nm and a minor peak maximum at 420 nm. Similar peaks
are observed in other hydroxo-bridged diiron enzymes like CmlA 20, and
Hemerythrin (Hr) 26 when in a low-spin, diferric state. The peak at 340 nm
manifests through the electronic charge-transfer exchange by the Fe 2 -O, which is
created by splitting the π-orbital electrons resonating between the two iron atoms
via an oxo-bridge 27. The intensity of the bands is less significant than those of
proteins with oxo-bridges, indicating that resonance is weaker due to the oxobridge being protonated. An Fe 2 -O bridge that forms in a linear fashion will
usually absorb at 420 nm and 500 nm. However, at the more acute angles of
114o to 130o, the lowest Fe 2 -O π-transition state at 500 nm blends with the
second lowest state at 420 nm, indicating a less-obtuse bridge form is present
with Orf78 28.
Titrating sodium dithionite to the protein, and subsequent reduction of the
diferric cluster, decreases the intensity of the 340 nm and 420 nm peaks, leading
to bleaching of the charge-transfer signal through the quenching of its π-orbital
resonance effects (Figure 1.4). Reduction is quick, inferring minimal difficulty for
electron access to the active site of Orf78. The oxidation of Orf78 from the
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diferrous state mimics CmlA and human dehydroxypusine hydroxylase by fully
oxidizing to the diferric state as observed by a rebound of the bleached 340 nm
and 420 nm charge-transfer bands 29. However, Stopped-flow data shows that
oxidation of Orf78 from the diferrous state in the presence of molecular oxygen is
a slow process, suggesting difficulty for the molecular oxygen cofactor to gain
access to the active site. This, in addition to an increased rate in the presence of
Phe-PCP Asn10 , suggests the presence of necessary events prior to the activation
of O 2 by the reduced enzyme.
The introduction of sodium azide to diferric Orf78 forms an additional πstabilized bridge, leading to an increase in absorbance for the 340 nm and 420
nm bands (Figure 1.5). Similar spectra are observed with biological non-heme
diiron enzymes, such as metHr and Hr 27, and synthetic constructs 30. However,
the concentration requirements of sodium azide necessary for bridge formation is
four-fold higher than required for CmlA and binding is not immediate, requiring
incubation at 4oC for longer periods to time to observe maximum peak
amplitudes. Two possible reasons for this is that access to the active site for
azide is restrictive or the distance between the two iron molecules is not optimal
to facilitate formation of the azide bridge.
The EPR spectrum of the diferric state does not induce a signal, which
confirms that Orf78 is a S=5/2-5/2 anti-ferromagnetically spin-coupled system
(Figure 1.6, top right). The absence of a signal at g=4.3 shows that there is both
little free iron in the sample and also that the two irons are not separate S=5/2
systems 31. Incubation with 0.5 molar equivalents of sodium dithionite produces

16

a S=5/2-2 spin-coupled system with an orthorhombic mixed-valent signal and
observable values of g z =1.96 and g y =1.86 at low temperature (Figure 1.6, top
left). These values are observed in other anti-ferromagnetically spin-coupled
systems, like RNR, when one-electron equivalent is added to the diferric enzyme
32

. The g x value is not observed, presumably blending into an extended g y

signal. This behavior is also observed in the mixed-valent signal for CmlA.
There is no signal when the sample is reduced with two-electron equivalents to a
diferrous state, indicating a S=2-2 spin-couple. This reinforces the conclusion
that the cluster is anti-ferromagnetically coupled since it is also observed in
similarly spin-coupled systems, such as MMO and Hr 33, 34.
The intensity of the mixed-valent EPR signal for Orf78 shows a
temperature-dependent that suggests the presence of a hydroxo-bridge between
the two iron molecules (Figure 1.6, bottom left). Increasing the temperature from
4K to 18K does not significantly alter the amplitude of the signal. However, the
signal decreases as the temperature is increased above 18K and is ultimately
lost beyond 39K. Similar tendencies are observed in other hydroxo-bridged
diiron proteins, like CmlA, MMO, and PAP, which have decreased relaxation
times due to the increased acidity of the associated irons 35. The presence of an
oxo-bridge would increase the relaxation time of the π-electron transfer between
the two iron atoms, preventing decay of the mixed-valent signal until higher scan
temperatures (>100K) are achieved 36.
Changes to the local environment, such as the presence of substrate or
cofactors, may alter the sensitivity of the relaxation state for the mixed-valent
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diiron species and observed through power saturation studies 37. As the power
increases, the relaxation state of the electrons sit at a higher energy level and the
signal decreases. Power saturation is also informative for determining what
power should be used to measure any EPR spectra so there is a reduction in
unwanted g-value broadening and signal reduction. For Orf78, a plot of the
power saturation curve shows a P 1/2 equal to 93.2mW ± 8.6mW (Figure 1.7), so
a high amount of power is needed to saturate the signal at 10K and overcome
the relaxation times of the mixed-valent signal. Plotting ln(P 1/2 ) for this value as a
function of temperature (K-1) gives a value of 4.53 at 10K, which is slightly higher
than CmlA (~3.8) and the hydroxo-bridged diiron Mitochondrial Alternative
Oxidase (~4.9) 20, 38. The values are assumed to be close enough to associate
similar power saturation values of Orf78 for all temperature ranges. Ideally, more
points would be preferred, but the slope, and the corresponding J value, of the
plot can be inferred due to the homology of the two enzymes and is assignable
as a hydroxo-bridge in the mixed-valent form.
Similarity of PCP domains
Three PCPs for the lysobactin biosynthetic pathway, PCP Phe3 , PCP Leu4 ,
and PCP Asn10 , provide substrate that are all β-hydroxylated prior to their
incorporation into the nascent peptide chain. A protein sequence alignment
(Clustal Omega) of the three contain a sequence identity of 40%-60% (Table
1.1). It has been theorized that this is due to gene duplication followed by
mutation of pre-existing modules, creating a useful and cheap mechanism to
expand the library of NRPS products 39, 40. However, the three PCP domains that
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facilitate β-hydroxylation of amino acids in the skyllamycin biosynthetic pathway
(incorporated in sky30 and sky31) have a sequence identity of 38%-60% 21.
Although the identity range is wider than the lysobactin pathway, variations for
both systems are mostly localized in the flanking regions of the four-helix bundle
of the PCPs. It is unclear what effects these flanking regions have on the overall
function of the module or their role in recruiting their respective β-hydroxylases.
Incorporation of PCP Phe6 , the only PCP in the teicoplanin biosynthetic pathway
(incorporated in dbv17) that is β-hydroxylated by the diiron hydroxylase Orf12,
into the sequence alignment with the lysobactin PCPs lowers the sequence
identity to 30% 41. However, a strong conservation of residues exists within the
core regions containing helices α2 and α3, which are presumed to contain the
binding motifs to the hydroxylase. Modeling the three PCPs from lysobactin to
the PCP from teichoplanin illuminate overlaps across all four helices, suggesting
that the PCPs for both systems adopt similar four-helix bundles in their active
forms (Figure 1.8).
Insertion of CmlP T from the Chloramphenicol biosynthetic pathway
(incorporated in orf8) 42, a Type II NRPS which contains a β-OH L-PAPA, into the
sequence alignment with the four Type I PCPs drops the sequence identity to
20%. The homology among all five T-domains also exemplifies this, as there is a
large drop-off in similarity upon the addition of the CmlP T PCP (Figure 1.9). A
model of CmlP T with any of the Type I PCPs above show incompatibility with the
Type II systems, as the conformation adopts a two-helix bundle in lieu of four.
The main discrepancy is the presence of random coil, which did not conform to
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the outfitted model, so does not conform to the four helix motif for the Type I
systems. This may infer that hydroxylases from Type I NRPS systems may not
recognize Type II NRPS systems and vise versa.
Despite the poor conservation between all five PCPs, certain aspects of
the core motif, mainly Lx[5]Gx[5]Fx[2]GGxSx[4]Q, remain consistent. In all cases,
residues for SfP recognition are similar enough on all five PCPs to allow the
transfer of Bodipy-PPant 43. The majority of conserved residues are also
hydrophobic, suggesting the interaction between the T-domain and the
hydroxylase are driven by Van der Waals forces or are less reliant on
electrostatics for their direct connection with each other. The PCP TycC3 from
the tyrocidine biosynthetic pathway contains a leucine residue that is presumably
associated with the interaction between the itself and Sfp 44, although there are
PCPs where the SfP recognition site could not be elucidated 45. Mutation of this
leucine from TycC3 inhibited recognition of SfP for the T-domain, but it is
unknown whether similar behavior occurs with hydroxylase/T-domain
interactions. Residues on the flanking ends of the PCPs may assist with proteinprotein interaction or they may provide subtle positioning of the four-helix bundle
so residues near the SfP recognition site can interact with the hydroxylase. Sitedirected mutations demonstrate that alterations of the α-helices of the PCP will
destabilize the interaction between the PCP and Sfp 46.
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Oxidation rates of PCPs with Orf78
A study of diferrous CmlA and its NRPS system shows an association
between the rate of oxidation of the enzyme and the presence of aminoacylatedor non-amionoacylated NRPS and molecular oxygen, which conclude that a
notable difference exists concerning oxygen-gating by the enzyme 20. In the
absence of NRPS, the rate of oxidation for CmlA is slow at 0.005 s-1. The rate is
relatively unchanged upon the introduction of apo- or holo-NRPS, with an
observed rate of 0.01 s-1. The rate of oxidation increases to 12 s-1 in the
presence of aminoacylated NRPS, suggesting that proper binding and channel
access for O 2 in CmlA occurs only in the presence of aminoacylated-NRPS.
This experiment was reproduced with Orf78 to determine the rate of
oxidation for the enzyme in the presence of native and non-native PCPs. Since
phenylalanine is one of the native substrates recognized by Orf78 and the
aromatic ring is similar to the native tyrosine substrate for PCP Tyr6 and the native
L-PABA substrate for CmlP, recognition is assumed to be driven by the binding
motifs on the PCPs and not the tethered amino acid. Poor expression and
solubility of PCP Asn10 prevents these experiments from being performed under
pseudo-first order conditions so the molar excess of PCP was kept at no more
than four times greater than Orf78 for all three T-domains.
All rate measurements are shown in Figure 1.10. The oxidation rates for
Orf78 in the presence of any apo-PCP and holo-PCP results in a slow rate of
oxidation of 0.004 s-1, similar to Orf78 in the absence of PCP and the rates of
CmlA under similar circumstances. The lack of a biologically significant rate
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indicates that either the apo- nor holo- forms of the PCP do not bind or that that
they bind but do not properly gate O 2 in the absence of tethered amino acid.
Orf78 in the presence of Phe-PCP Asn10 shows fits with a double exponential, with
an initial phase of 0.2 s-1 followed by a second phase of 0.005 s-1. The initial
phase may be a mixture of the PCP binding event and quick oxidation and a slow
oxidation rate due to unbound enzyme, and artifact of the experiment not
adhering to pseudo-first order conditions. The second phase is likely O 2 gating
into Orf78 unbound to PCP Asn10 . The rates of Orf78 in the presence of PhePCP Tyr6 and Phe-CmlP T is monophasic with an oxidation rate of 0.004 s-1,
matching the oxidation rate of Orf78 in the absence of PCP. This suggests there
is another factor other than substrate recognition that is inhibiting binding of the
hydroxylase to the PCP, such as the proposed incompatibility with CmlP T
proposed earlier or the presence of higher dissociation constants between Orf78
and non-native T-domains.

1.4 DISCUSSION
It is necessary to study monooxygenases homologous to CmlA enhance
the flexibility of enzyme choice when engineering a biosynthetic gene cluster.
This choice may allow for the recognition of certain modules in a semi-specific
manner and is important when attempting to build libraries of antibiotic-like
compounds. Ideally, the selection of a hydroxylase for an engineered NRPS
system would be dependent on its solubility in-vivo, redox partners, and its ability
to properly recognize and utilize cofactors required to perform the necessary
chemistry. Experiments in-vitro with Orf78 attempt to discern the viability of
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combining the use of an enzyme from one pathway with PCP components from
non-native systems in an effort to discern the specificity of these interactions.
However, the results do not favor the use of non-native enzymes with NRPS
systems without modifying their components to promote a higher degree of
recognition between the two. Although there is an interaction between Orf78 and
PCP Asn10 , there is no interaction with the non-native aminoacylated-PCPs.
The oxidation rate of the Orf78/Phe-PCP Asn10 complex does not reach a
level to be considered biologically relevant, as bacterial defenses would be
overwhelmed with such slow production. This contrasts with the oxidation rate
for CmlA in the presence of L-PAPA-CmlP AT at 12 s-1, rising two orders of
magnitude higher than any of the rates associated with Orf78. One argument is
that the dissociation constant of the interaction is much higher than published for
other hydroxylase/PCP systems, such as P450 sky or P450 nikQ , and ratio of PCP
to Orf78 is too low to visualize quick oxidation. This led to a slower rate for the
first phase than would otherwise be observed. It is currently unknown if there are
additional interactions between the hydroxylase and the A-domain that assist
with recognition and helps to guide the interaction. Unfortunately, the rate for
CmlA/L-PAPA-CmlP T is unknown, so a true comparison between Orf78/PCP Asn10
and CmlA/CmlP AT cannot be obtained. The inability to clone out any soluble
forms of the AT domains from lysobactin system prevented testing that
hypothesis with any complexes with Orf78.
The inability to properly model CmlP T based off of published NMR
structures suggests potential problems with interactions between Orf78 and

23

CmlP T , explaining the absence of reactivity during oxidation experiments with
Orf78. However, is should be noted that the Phe-PPant may not sit correctly on
the PCP if the para-amino group is influences the interaction of substrate stability
on the T-domain and destabilizing its binding to the hydroxylase. In addition, the
NRPS from the chloramphenicol pathway is unimodular and may not have
sufficient complexity compared to their multimodular counterparts, meaning the
modular components of CmlP AT may not be homologous with Type II NRPS
systems and cannot interact with Orf78. However, Phe-PCP Tyr6 displays a
monophasic rate comparable to Orf78 alone with O 2 . This is surprising since its
sequence aligns the alpha-helical regions well for PCP Tyr6 and PCP Asn10 .
Although the similarity between these two PCPs appear high enough to assume
some interaction between the hydroxylase and the Phe-PCP Tyr6 domain, this
illustrates the subtlety of the structural differences between the PCPs from these
two systems and represent the fine-tuning that must occur to properly lock the
complex into place.
Although the enzyme purifies as a dimer, the issues concerning the
protein-protein interaction between an enzyme with a singly-loaded cluster per
dimer an the PCP domain may affect the kinetic rates, although these effects are
not known. The incompleteness of iron-loading may be due to iron lability in the
unloaded monomer. Alternatively, the unloaded monomer may be forced into a
different structural conformation by the loaded monomer and inherently does not
load upon dimerization. One example involves the incomplete loading of the
dimeric diiron enzyme hp53R2, which fully loads one cluster into one monomer
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but only partially loads the second cluster in the second monomer due to the
loaded monomer exerting conformation dominance over the partially loaded
monomer 47. However, the result for Orf78 differs from CmlA, which purifies with
two complete clusters per dimer; so nuances concerning the monomeric
influences for the dimeric form may exist for Orf78. If the enzyme solely operates
on the NRPS system, as its placement in the lysobactin operon suggests, then
there is no need for a two fully-loaded clusters per dimer to do the necessary
chemistry, as only one monomer could bind at a time to the larger, multimodular
complex. Since the unloaded monomer is presumably distorted in a manner that
prevents iron-loading, it is unknown whether PCP Asn10 will prioritize the loaded
monomer over the unloaded one. Additionally, any PCP bound to the unloaded,
non-catalytic monomer will lower the rate of oxidation since the effective
concentration of PCP will be lower than previously calculated. The PCP
concentration is already poised for sub-pseudo first order kinetics with only a
four-fold excess to Orf78, so the effective concentration will be halved at two-fold
to Orf78, assuming the PCP binds with equal preference for each monomer.
Alternatively, PCP binding to one monomer may inhibit binding to the unbound
monomer.

1.5 CONCLUSION
Orf78, the hydroxylase from the lysobactin biosynthetic pathway, was
purified and characterized as a dimeric, diiron enzyme. The hydroxylated PCP
domains from the lysobactin pathway are compared to view similarities in
homology as well as to compare them to non-native hydroxylated PCPs from the
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Type I NRPS teicoplanin and Type II NRPS chloramphenicol biosynthetic
pathways. Oxidation experiments were performed to test for protein-protein
interactions between these PCPs and Orf78, with the only interaction recorded
with Orf78’s native T-domain, PCP Asn10 . The reasoning for some T-domains
being hydroxylated and not others is still an aspect of ongoing research by both
our and other labs.
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Figures and Tables

Figure 1.1: Diagrams of the hydroxylation reaction with P450sky and the
lysobactin antibiotic. Top panel - a diagram of the pre- and post-hydroxylated
PCP with affected amino acids. Bottom panel – a diagram of the depsipeptide
antibiotic lysobactin. Red lettering indicates the locations of hydroxylation by
Orf78.

Figure 1.2: Diagrams of Orf78 endogenous ligands and the active-site
structure. Top panel – sequence alignment for the endogenous iron ligands in
the diiron hydroxylases associated with the biosynthesis of lysobactin (Orf78),
chloramphenicol (CmlA), and teicoplanin (Orf12). Bottom panel – a diagram of
the proposed active site symmetry for Orf78 based off of the crystal structure of
CmlA.
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Figure 1.3: Size-exclusion chromatography plot of Orf78. The elution profile is
present in the insert. 25 µM protein was directly injected onto the column
following purification. The elution profile shows a dimeric form of the enzyme
with no peaks suggesting monomeric or other oligomeric forms of the protein,
with extraneous peaks eluting earlier and later being contaminants present
during purification.

Figure 1.4: Reductive titration of Orf78. The plot shows the bleaching of the
band at 340 nm as sodium dithionite reduces the enzyme from the diferric to the
diferrous state. The inset shows a plot of the titration points and show the
requirement of 2.3 electrons to fully reduce the enzyme, confirming the presence
of a diiron cluster.
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Figure 1.5: Optical spectrum of Orf78 incubated with sodium azide. 3.5
µM enzyme was incubated with 8 M sodium azide, 100 mM HEPES, pH=7.5.
The pronounced peaks at 340 nm and 460 nm are due to enhancements of the
charge-transfer bands between the two iron atoms caused by the addition a
bridging azide molecule.
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Figure 1.6: EPR spectra of mixed-valent Orf78, dithionite saturation,
power saturation, and temperature saturation. Top left – mixed-valent EPR
spectrum of 200 µM Orf78. Top right – EPR spectra of Orf78 with 0.4, 0.8, 1.0,
and 2.5 molar equivalents of electrons, demonstrating the transition from the
diferric to mixed-valent to diferrous state. Bottom left – temperature saturation of
the mixed-valent signal. The signal bleaches as temperatures reach 40K,
indicating the presence of a hydroxo-bridge between the two iron atoms. Bottom
right – three spectra of the mixed-valent sample demonstrating the relationship of
signal degradation as a function of increasing power.
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Figure 1.7: Power saturation curve for Orf78 at 10K. The sample
consists of 200 µM mixed-valent Orf78. The half-saturation value is 2 mW higher
than CmlA, but reasonably similar to justify assignment of the same J coupling
constant.

Figure 1.8: Molecular models for PCP Asn10 , PCP Tyr6 , and CmlP T . Models
of PCP Tyr6 from the teicoplanin pathway and CmlP T from the chloramphenicol
pathway based off of a model of PCP Asn10 from the lysobactin pathway (derived
from PDBID# 1DNY). The panel on the right duplicates the models on the left
but with a 90o rotation. Note the absence of two terminal helices for CmlPT that
do not align in the model.
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Figure 1.9: Sequence alignment for PCPs from lysobactin, teicoplanin,
and chloramphenicol pathways. Sequence alignment showing homology among
the three hydroxylated PCPs for lysobactin (green), lysobactin PCPs with the
addition of the PCP from teicoplanin (blue), and also lysobactin and teicoplanin
PCPs with the addition of the PCP from chloramphenicol (red). There is slight
drop in homology between the lysobactin and teicoplanin PCPs, both derived
from Type I NRPSs. The homology heavily decreases upon the addition of the
chloramphenicol PCP, derived from a Type II NRPS.

Figure 1.10: Oxidation of reduced Orf78 with aminoacylated PCPs. 25
µM reduced Orf78 was shot against either a four-fold excess of L-phe-PCP Asn10 ,
ten-fold excess of L-phe-PCP Tyr6 , or ten-fold excess of L-phe-CmlP T and 1 mM
O 2 . The results are biphasic for Orf78’s native PCP, but monophasic for the two
non-native PCPs.
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Table 1.1: Sequence identity of 3 cognate and 2 non-cognate PCPs for P450sky

The average identity of the three lysobactin PCPs is between 40%-60%.
The identity of those three to the teicoplanin PCP drops to 30%. Furthermore,
their identity compared to the PCP from Chloramphenicol is further lowered to
20%.
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CHAPTER 2
DETERMINATION OF THE ROLE OF A NON-RIBOSOMAL PEPTIDE
SYNTHETASE IN THE RECOGNITION OF A NON-COGNATE TAILORING ENZYME
2.1 INTRODUCTION
Bacterial synthesis of antibiotics has been intensively studied over the
past three decades, but have not ranged beyond the analysis of individual
biosynthetic pathways. As more of the individual components of the machinery
are elucidated, the creation of novel synthetic pathways that are transformable
into a bacterial host for the mass production of new products are providing a
natural change in direction for future research. Alteration of currently understood
non-ribosomal peptide synthetase (NRPS) systems provides a basis for this
research; however, their use in conjunction with cognate tailoring enzymes may
enhance the range of possible products. Although these cognate enzymes have
been elucidated in several systems 1-7, their interactions with the NRPS subunits
are unclear, as well as their potential interactions with non-native systems. An
understanding of how these processes behave may assist in the choice of gene
combinations, potentially from multiple pathways, necessary to form newlydesigned operons that are capable of synthesizing a new natural product.
The number of biosynthetically derived antibiotics vary greatly due to the
system-dependent combinations of both natural and non-natural amino acids that
41

may be incorporated during the peptide synthesis. Each system is driven
by NRPS-specific modules that choose, modify, and incorporate the amino acids
that form the final product. This leads to a multitude of potential enzymes and
domains that specialize in substrate selection and potential chemical
modification. A couple of well documented examples include the lactonization of
skyllamycin by a thioesterase as well as the incorporation of sugars onto the
peptide backbone of vancomycin by methylases 8, 9. To further narrow the
reaction specificity involving sugar incorporation above, dehydrogenases have
been observed that are selective for either O- or N-methylation in various
pathways 10-13. To stress the importance of these chemistries, these types of
translational and post-translational modifications act as inhibitors of cellular
function within a target cell necessitating that the producer counteract the effects
of these inhibitors while the antibiotic producer contains immunity to their effects
14, 15

, as is the case with the methyltranferase Cfr in S. aureus, a protein

responsible for the methylation of several residues on the 23S ribosomal RNA
that inhibits the binding of chloramphenicol 16.
The creation of a synthetically created antibiotic biosynthesis pathway is a
major milestone for researchers, as it will allow for the formation and testing of
compounds different from those found in nature. Theoretically, the effects of
these compounds would be difficult for bacterial targets to overcome since the
scaffold of their resistance machinery cannot compensate for compounds with
greatly different chemical properties from those already present. One likely
avenue of study is the manipulation of existing pathways that may lead to the
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discovery of new drugs, including techniques that create a plug-and-play system
that can create libraries of similar compounds through modifications of simple yet
necessary chemistries that can be tested for antibiotic effectiveness. An
example is the incorporation of different chemistries through the use of enzymes
that operate as individual in trans modifiers, rather than in cis domains that are
incorporated into the NRPS machinery 5, 17, 18. For example, hydroxylases such
as P450sky (CYP163B3) are expressed as gene product independent of its
NRPS within the skyllamycin biosynthetic operon 8. Not only is the protein more
likely to be soluble since it is not excised from a larger complex, but the residues
that form the recognition interface may be used to modify an NRPS module for
hydroxylation. Attempts to incorporate an enzyme into an NRPS module may
lead to instability due to interference with the inter-modular interactions
necessary for the incorporation and passing of the amino acids through the
NRPS machinery 19, 20. Therefore, it is best to avoid direct modification of the
NRPS modules.
Since the addition of a separate, individual protein is less troublesome
than the modification of an existing module, the former became the focus of this
research utilizing P450sky from the skyllamycin biosynthetic pathway. Work by
Cryle et al has demonstrated that P450 sky is a monooxygenase that incorporates
a hydroxyl group into the beta carbon of L-leucine, O-methyl-L-tyrosine, and Lphenylalanine while appended on the thiolation-domain during the synthesis of
skyllamycin 21. The P450 contains a thiolate-ligated porphyrin cofactor in the
protein’s active site that receives electrons from a ferredoxin that docks on the
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proximal face of the enzyme. The structure of the protein shows a deep channel
from the surface residues to the porphyrin (~23 Angstroms). The F and G
helices are culpable for the binding of the T-domain, although the exact residues
responsible are unknown 22. Interestingly, the crystal structures published by
Cryle et al. suggests that there is minimal conformation change between the
unbound state and the bound state (PDB ID: 4PWV, 4LOF; this work). A crystal
structure showing P450sky bound to PCP Tyr7 of the skyllamycin pathway by way
of ligation of an PPant-imidazole ligand to the heme iron suggests that the
interactions are driven by hydrophobic residues at the interface (PDB ID: 4PWV).
The overall hydrophobic character of the skyllamycin antibiotic allows for
the inhibition of the mechanism involved with the biosynthesis of the bacterial cell
wall. However, the presence of multiple hydrophobic residues decreases its
solubility - allowing for an evolutionarily viable explanation for the addition of
hydroxyl groups to the peptide. Other residues were also tested, mostly
consisting of hydrophobic L-, and D-amino acids on all three T-domains. The
results concluded that D-amino acids are not hydroxylated and non-cognate
amino acids (tryptophan and tyrosine) were only hydroxylated with reduced
efficiency. There were no tests on amino acids with charged side chains to
determine their effectiveness for hydroxylation. Therefore, the tethered amino
acid does appear to play a small, but important, role in the overall recognition of
the hydroxylase to the substrate-bound carrier. The structure of the imidazoleligated T-domain shows interactions with side chains in the channel with the
PPant residue that extends toward the active site from the T-domain, enhancing
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the binding interface. However, there is currently no evidence of complex
formation with the apo- or holo-T-domain, as there is no product to test for
activity. The understanding of the hydrophobic nature of the interaction is not yet
understood, as no experiments have been performed under high-salt conditions.
P450nikQ (CYP162A1), an enzyme that operates in trans to the NRPS in
the nikkomycin biosynthetic pathway and is homologous to P450sky, interacts
with a unimodular NRPS (NikP1) and is responsible for the β-hydroxylation of a
tethered histidine residue. Both genes are located within the same operon and
are expressed as single proteins. P450 nikQ and P450 sky share an amino acid
sequence similarity of 53.3% along with a sequence identity of 33.6%, allowing
for a reasonable comparison of the two as homologs. A model of P450nikQ
based on the substrate-free P450sky structure (PDB ID: 4L0F), shows a
preference of polar residues leading to the active site of the enzyme, whereas
P450 sky contributes mostly hydrophobic residues with a preference for
phenylalanine. These residues may assist in guiding the tethered amino acid
through the channel and may dictate which side chains are acceptable for
recognition by the enzyme. The exterior surface of the enzymes shows little in
shared similarity, other than a patch of cationic residues on the surface proximal
to the porphyrin that presumably binds an unidentified ferredoxin. The binding
interfaces for the P450s that are involved with their interactions with the Tdomains show little similarity, consisting of residues that often differ in polarity.
This is important given that the high amount of similarity between the T-domain
for NikP1 and PCP Tyr7 , (51.3% identity and 35.5% similarity) would imply that
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both P450 enzymes would be able to recognize T-domains from each other’s
systems. This gives credence to the conclusions by Cryle et al. concerning
hydrophobic forces driving the interaction with the enzyme and the NRPS.
Under canonical conditions involving redox partners, the shift from a lowspin to high-spin state raises the potential of the enzyme, a gating behavior
necessary to deter the unnecessary transfer of electrons to enzyme that is not
substrate-bound and decreases the production of subsequent radical oxygen
species 23. The rise in potential originates from the movement of an electron
from a lower energy orbital to a higher energy orbital, instigating a state of
greater reactivity with molecules that are in energetically low triplet state, such as
molecular oxygen. P450sky, to the contrary, does not exhibit a spin-shift upon
binding with aminoacylated NikP1AT due to its ferric high-spin redox potential
resting around -300 mV, lower than CYP101A1 which has potentials for low-spin
at -303 mV and high-spin at -173 mV 24, 25. Among the differences between the
homologs, there is a small, observable shift from low-spin to high-spin for
P450sky upon the addition of the L-Tyr-PCP Tyr7 carrier protein, indicating that the
redox potential for the bound species is higher in P450sky. Due to the lack of
high-spin for P450nikQ, Wise confirmed through an EPR titration that L-HisNikP1AT binds with P450nikQ, along with the unexpected result of the histidine
side group ligating to the iron of the porphyrin. Using this method of analysis, the
dissociation constant was judged to be between 50-100 µM and there is currently
no evidence suggesting a reason for this high of a K D .
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The formation of peptide-based antibiotics requires a modular system that
may be uni- or multimodular, where each module contains multiple domain units
that cooperate for the creation of the antibiotic. The skyllamycin biosynthetic
pathway involves 11 modules in the creation of the depsipeptide, with each
module involved in the activation and incorporation of a specific amino acid. The
size of these systems, ranging from 70 kDa for the unimodular nikkomycin NRPS
to greater than 1.0 MDa with the 8 module syringomycin NRPS and the 11
module cyclosporine A NRPS, inhibit easy study since solubility may necessitate
potential interactions among other modules within the system 26, 27. Recent
studies of these multimodular pathways have focused on excising certain
domains or modules and observing the synthesis of small portions of the
antibiotic or the conferrence of specificity towards particular amino acids 7, 28, 29.
However, it is difficult to understand the interactions between an enzyme
operating in trans to a NRPS utilizing such a technique. There may be
interactions between the enzyme and areas on the NRPS that may not have
been excised for study, either other domains within the same module or even
between other modules within the NRPS pathway and the exogenous enzyme.
One method to bypass this obstacle is to observe a unimodular system
containing a minimum number of domains. In this manner, the interactions
between an exogenous enzyme and an NRPS can be studied without the loss of
other, more complex interactions.
The biosynthetic mechanism for the creation of these antibiotics begins with
tethering an amino acid to a phosphopantetheine (PPant), derived from
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Coenzyme A (CoA) and ligated to a Thiolation (T) domain, which assists with
transportation of the substrate throughout the module. The importance of the T
domain cannot be understated as it inability to determine the substrate leaves it
potentially open for the hydroxylation of any amino acid residue that is attached
to it or improper protection of the attached amino acid, depending on its
positioning post-attachment 5, 21. The T-domain is subsequently covalentlyattached to an Adenylation (A) domain, which activates a specific amino acid to
be incorporated into the nascent peptide chain of the antibiotic and attaches the
residue to the T-domain 30, 31. The final covalently-attached domain that is
integral for multimodular NRPS systems is the Condensation (C) domain, whose
importance lies in accepting the nascent chain from the immediate upstream
module and incorporating the amino acid of the current module into the growing
chain 29, 32. The formation of these individual modules must facilitate interactions
with the PPant and the active sites of both the A and C domains, which
necessitates constant and drastic conformational shifts as the machinery
operates to extend the length of the peptide. The final module of the pathway
contains a Thioesterase (TE) domain, which cleaves the peptide from the NRPS
complex or promotes the formation of a depsipeptide through the formation of an
intramolecular ester 33, 34.
The complexity of the multimodular system makes it difficult to synthetically
produce biosynthetic pathways, so a more viable route is to study a unimodular
system. The status of P450sky as a homolog of P450nikQ qualifies the use of
the NikP1 NRPS system for this cross-platform study. NikP1 is a unimodular
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complex consisting of an A and T domain that activate and, in the presence of
P450 nikQ and its associated redox partners, β-hydroxylate a histidine residue.
Other than data supporting general hydrophobicity, the characteristics describing
the interaction between P450nikQ and NikP1 have not been previously
elucidated, so it is unclear which surface residues are necessary for their
interaction. It is not currently understood if there is a role for electrostatic
residues necessary for a catalytically-relevant binding motif.
Wise collected data by size-exclusion chromatography demonstrating that
P450 nikQ binds in the presence of apo and aminoacylated forms of NikP1, but not
the holo form. The solved structure of an excised di-domain derived from the
gramicidin biosynthetic pathway (PDBID: 5ES6) show that the holo form is locked
into a conformation where the T domain is locked into the A domain, awaiting
aminoacylation 35. This may be informative in discerning which intermediate
conformations of the NRPS are available for binding by an exogenous enzyme.
The elution times from the SEC are variable depending on whether P450nikQ is
interacting with the apo or aminoacylated forms, with the correct molecular
weight calculated when bound to the aminoacylated form but an earlier elution
time for the apo. This was concluded to be different geometries of the complex
formed between P450nikQ and NikP1. However, there have been no studies
detailing what these possible conformations could involve.
Although the T-domain is catalytically inert, the presence of a PPant is
necessary for the interaction between itself and other modules/tailoring enzymes,
even without conformational changes between the apo and holo forms of the
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protein 22, 36. Prior to the binding event, the loaded T-domain may coil the PPant
around its own four-helix bundle, similar to the behavior of the acyl-PPant
attached to acyl carrier proteins 37-39. This “switchblade” mechanism protects the
thioester bond from hydrolysis when present in the reducing, aqueous
environment of the cell. This also allows surface residues of the T-domain to
remain exposed for recognition by exogenous enzymes. This motif has not been
observed in any holo constructs of PCP domains, so the location of the PPant
during the intermediates involved between attachment of the PPant and
aminoacylation of the T-domain have not been elucidated. The sites of
interaction for the amino acid reside itself are not presently understood, but the
selectivity for the beta position of the amino acid suggests that the amine may be
stabilized by residues in the protein active site. It is currently unknown how
dissociation of the enzyme from product-bound NRPS is triggered and if
structural changes of the enzyme or NRPS, or a combination of the two, may be
involved.
In this chapter, binding affinities between NikP1 and its cognate and noncognate P450 hydroxylases will be probed. This is done through small molecule
titration assays. In addition, EPR data recording the interaction from the
perspective of both the porphyrin and the substrate is reported with results
suggesting the non-cognate P450sky binds to the A-domain with no affinity to the
native L-histidine substrate.
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2.2 MATERIALS AND METHODS
Sub-cloning of P450sky
The codon-optimized gene for P450sky was purchased from DNA 2.0 in a pJex
vector containing a T5 promoter and C-terminal 8x polyhistidine tag. The
sequence included flanking restriction sites in the following pattern, 5’-NdeIP450sky-XhoI-3’. The gene was subsequently sub-cloned into a pET21b vector,
which included a T7 promoter and an N-terminal 6x polyhistidine tag.
Expression of P450sky
The plasmid was transformed into chemically competent BL21 (DE3) cells that
have been previously transformed with pChuA (purchased from Addgene:
plasmid #42539; deposited by Alan Jasanoff). This vector allows for the uptake
of porphyrin from the media, ensuring that the rate-limiting step in the P450
biosynthesis is not the lack of Fe-Protoporphyrin IX 40. A single colony was
transferred to an overnight starter culture and 10 mL were transferred to
inoculate each liter of media, which consists of the following for 500 mL: 12 g
tryptone, 1 g peptone, 12 g yeast extract, 0.5% glycerol, 50 mM potassium
phosphate, dibasic and potassium phosphate, monobasic, pH=7.1. The following
additives were included to enhance native peptide and porphyrin production prior
to the induction of the chuA plasmid: 10 mM casamino acids, 5 mM δaminolevulinic acid, and 1 mM Thiamine-HCl. Antibiotic resistance genes were
activated on each plasmid with 50 mg/L kanamycin and 100 mg/L ampicillin. The
culture grew at 37oC, 210 rpm until the OD 600 =0.65, at which point the
temperature was reduced to 20oC and 5 mg/L of hemin (in DMSO) was added to
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each flask. After 30 minutes, both genes were induced with 50 µM IPTG and the
culture incubated for an additional 18 hours prior to harvesting. The culture was
centrifuged at 6000 rpm for 15 minutes and stored at -80oC until purified.
Purification of P450 sky
The cell pellet was resuspended in 250 mL of buffer consisting of 50 mM Sodium
phosphate, monobasic, 300 mM Sodium chloride, and 10 mM imidazole (Buffer
A). The solution was sonicated seven times on two minute cycles followed by 5
minutes of stirring on ice. The lysate was cleared by centrifugation at 16000 rpm
for 35 minutes and the supernatant loaded onto a 50 mL column of Ni-NTA resin
pre-equilibrated with Buffer A. The column was washed with Buffer A + 10 mM
imidazole followed by elution with Buffer A + 240 mM imidazole. The eluent was
concentrated and dialyzed twice in 4 L of 50 mM HEPES, pH=7.5, 10% glycerol.
After dialysis, the protein was loaded onto a 50 mL column containing
diethylaminoethyl (DEAE) anion-exchange resin pre-equilibrated with 50 mM
HEPES + 5% glycerol (Buffer B). The protein was subsequently washed with
Buffer B + 20 mM sodium chloride followed by a gradient elution in Buffer B
supplemented with 50 mM – 300 mM sodium chloride over a 300 mL volume.
The fractions containing absorbance A 417/280 >1.1 were pooled and dialyzed
twice in Buffer B, concentrated to a manageable volume, and flash-frozen for
storage at -80oC.
Expression of holo-NikP1AT
The expression procedure has been outlined in 24. Briefly, the plasmid containing
the gene-of-interest was transformed into chemically competent BL21 cells co-
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transformed with sfp plasmid. A starter culture was created with a single colony
and 10 mL of the starter were inoculated per liter of culture, which consists of
Luria-Bertani broth + 50 mg/L of Kanamycin. The cultures were grown at 37oC
until an OD 600 =0.8 was reached, when the temperature was lowered to 18oC.
After 30 minutes, the vectors were induced with 200 µM IPTG and the cultures
incubated for 20 hours. The culture was then spun down at 6000 rpm for 15
minutes and stored at -80oC.
Purification of holo-NikP1AT
Cells were resuspended in 350 mL of Buffer A and sonicated 10 times
with 2 minute cycles with a 5 minute break between cycles. The lysate was
cleared by centrifugation at 16000 rpm for 60 minutes and the supernatant was
loaded onto a 50 mL Ni-NTA column pre-equilibrated with Buffer A. The column
was washed with Buffer A + 10 mM imidazole, eluted with Buffer A + 240 mM
imidazole, and 5 mL fractions collected. Protein was isolated by observing the
absorbance at A280, with these fractions pooled and concentrated prior to
dialyzing twice in 2 L of 100 mM HEPES, pH=7.5 + 10% glycerol. Following
dialysis, the protein was further purified using a S-200 Size Exclusion
Chromatography (SEC) column equilibrated with 100 mM HEPES, pH=7.5. The
purity of the fractions was determined by SDS-PAGE, with the fractions
containing the highest purity pooled and concentrated, flash-frozen, and stored at
-80oC.
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Cloning of PCP Tyr7
The codon-optimized gene for PCP Tyr7 was purchased from DNA 2.0 and
shipped in a pJex vector containing a T5 promoter and C-terminal Fh8 calciumdependent protein serving as an HIC affinity tag 41. The gene was subsequently
cloned into a pDB.His.GST vector containing the following sequence: 6xhis-GSTTEV-PCP Tyr7 using the following primers (restriction sites are italicized):
Forward: 5’-agagtgGAATTCgctccgggtccagac-3’
Reverse: 5’-agagtgCTCGAGttagccaccgatcagcac-3’
The gene was amplified using Pfu polymerase (Addgene plasmid #12509)
42

and a BioRad T100 Thermo Cycler for 35 cycles using the following conditions:

denature- 50 sec at 94oC, anneal- 50 sec at 66oC, elongation- 2 min 15 sec at
73oC. The PCR product was gel-purified and digested overnight at 37oC with
EcoRI and XhoI. The digest mixture was again gel-purified and ligated to
similarly digested vector with T4 DNA ligase (Promega) overnight at room
temperature. Plasmid was extracted from several colonies and the integrity of
the gene was verified by sequencing at Eton Bioscience, Inc.
Expression of apo-PCP Tyr7
The plasmid was transformed into chemically competent BL21 (DE3) cells
and a single colony used to inoculate a starter culture. 10 mL of the starter
culture were used as inoculant per 1 L of Luria-Bertani broth and the culture
incubated at 37oC until the OD 600 =0.6. Upon reaching the OD, the temperature
was dropped to 30oC and the cultures were incubated for an additional 30
minutes followed by induction with 200 µM IPTG and shaken for 20 hours at 210
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rpm. The cells were then centrifuged at 6000 rpm for 15 minutes and stored at 80oC.
Purification of apo-PCP Tyr7
The pellet was resuspended in Buffer A and sonicated 10 times with 2minute cycles and intermittent 5 minute breaks. The lysate was cleared by
centrifugation at 16000 rpm for 30 minutes and the supernatant loaded onto a 30
mL Ni-NTA column pre-equilibrated with Buffer A. The column was washed with
Buffer A + 10 mM imidazole and the protein eluted with Buffer A + 240 mM
imidazole. The eluent was dialyzed twice in 2 L 100 mM HEPES, pH=7.5, 100
mM sodium chloride. The protein was concentrated, flash-frozen, and stored at 80oC.
Synthesis of Bodipy-Coenzyme A
This procedure is a modified version from 43. 10 mg of Coenzyme A (CoA,
Sigma-Aldrich) were dissolved in acetonitrile with 2 mg of Bodipy-FL (Thermo
Fisher Scientific) in a dark environment. The reaction was stirred at room
temperature for 5 minutes prior to incubation at 4oC for an additional 3 hours.
The free Bodipy-FL was extracted several times with a 15-fold excess of ice-cold
diethyl ether. The acetonitrile phase was dried in the dark under a stream of
nitrogen gas to concentrate the material and evaporate residual diethyl ether.
The solution was aliquoted and stored at -80oC.
Verification of T-domain/SfP interaction
Approximately 100 µM of the holo-NikP1AT was mixed in a solution that
contained 50 mM HEPES, pH=8.0, 250 µM Bodipy-CoA, 200 nM SfP, and 200
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mM magnesium chloride. The reaction was incubated for 1 hour at room
temperature and the reaction mixture was separated on a 12% SDS-PAGE gel
with the location of the Bodipy-CoA verified via transilluminator at 300 nm.
Batches that did not contain Bodipy at the same molecular weight as the protein
were used immediately for downstream experiments. Batches that did contain
Bodipy at the protein’s molecular weight were considered apo- protein and the
batch was subsequently treated with free CoA in the presence of SfP.
In a similar manner, the serine residue on the PCP necessary for
phosphopantetheine transfer was verified to be exposed using the same
technique as holo-NikP1AT. However, unlike the AT domain, SDS-PAGE was
used to verify the presence of Bodipy at the molecular weight of the GST-PCP Tyr7
fusion product. If Bodipy was not present at the correct molecular weight, the
protein batch was discarded with the assumption that it was irreparably
misfolded.
Aminoacylation of holo-NikP1AT with L-Histidine
The reaction conditions are modified from previous procedures 24, 44. A
reaction mixture of containing 50 mM HEPES, pH=8.0, 200 mM magnesium
chloride, 20 mM L-Histidine, and 200 µM holo-NikP1AT were incubated at room
temperature for 1 hour followed by incubation at 4oC for 1 hour. The solution
was desalted into 100 mM HEPES, pH=7.5 followed by verification by SEC,
which also served as a purification step to remove non-aminoacylated NRPS.
The protein was flash-frozen and stored at -80oC.
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UV-Vis measurements
All measurements were made on an Agilent 8453 UV-Vis
Spectrophotometer using quartz cuvettes (Starna Cells, Inc.) with a path length
of 10 mm and a 4 mm slit width with or without an anaerobic screw-cap. The
ferric spectrum was obtained by adding 5 µM protein with 50 mM HEPES + 0.3
molar equivalents of methyl viologen and degassing for 15 minutes prior to a
spectrum being taken. The reduced species was observed by taking the ferric
sample and adding 1.5 - 2 molar equivalents of sodium dithionite. The ferrousCO complex was produced by adding carbon monoxide to the reduced species
and obtaining a spectrum after several seconds. The spectrum of the
P450sky/His-NikP1AT complex involved incubating 5 µM of P450sky with 10 µM
His-NikP1AT on ice for 1 hour, centrifuging the sample at 4oC at 16000 rpm for
10 minutes and observing the signal.
Titrations were carried out on P450sky with imidazole and sodium
cyanide, two ligands that bind tightly to more traditional P450s, such as
CYP101A1. 100 µM imidazole was titrated into 5 µM enzyme and incubated for
one minute for each data point, for a total of ten. Separately, 5 mM sodium azide
was titrated with 5 µM P450sky and incubated for 1 minute for each data point,
for a total of ten. These data were analyzed using OriginPro 8.6 software, with
the dissociation constants determined by fitting with the Michaelis-Menten
equation.
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Characterization of the P450 sky /His-NikP1AT complex
In an Eppendorf tube, a mixture of 10 µM P450sky and 100 µM HisNikP1AT were incubated on ice for 2 hours then spun down at 4oC at 16000 rpm
for 5 minutes. The protein mixture was then run through a 0.22 um filter and
injected onto an ATKA FPLC (GE Healthcare) equilibrated with 100 mM HEPES,
pH=7.5 and 150 mM sodium chloride. The flow rate was set to 0.15 mL/min and
a fraction collector was set up to collect in 0.5 mL aliquots. Following the run, the
fractions were observed on the UV-Vis at both 280 nm (aromatic residues) and
417 nm (heme). The heme-containing fractions were verified on a 12% SDSPAGE gel to confirm the presence of both proteins.
Measurement of the P450sky-oxy complex by Stopped-flow
The measurement of the decay rate of the ferrous-oxy complex was
performed on an SX20 Stopped-flow spectrophotometer (Applied Photophysics)
for accurate visualization and rate measurements. The temperature of the
experiment was set to 4oC and data was collected either utilizing a PDA set up in
logarithmic mode for 1 second with 1000 time points or using a PMT detector
with 5000 time points. 5 µM of P450 sky in 50 mM HEPES, pH=7.5 with the
addition of 0.3 molar equivalents of methyl viologen was degassed with nitrogen,
reduced with two molar equivalents of sodium dithionite, and loaded onto syringe
A, previously washed with sodium dithionite followed by degassed buffer.
Syringe B consists of 50 mM HEPES, pH=7.5 supplemented with 2 mM O 2 . The
data was visualized as well as fit to a single exponential using Applied
Photophysics Pro-Data SX software.
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EPR measurements
Spectra of the low-spin enzyme were collected on an EMXplus X-band
EPR (Bruker) at 16K with 12 mW power and a microwave frequency of 9.834
GHz. 20 scans from 400-4000 gauss were averaged to obtain a final spectrum.
The data were collected and analyzed on either Bruker Xenon software suite or
the SpinCount software package. Determination of the g-values were performed
by the use of the equation g = (71.4484v) / B, where magnetic field, B (mT) and
the microwave frequency, v (GHz). Ferric samples were set up with 200 µL of
800 µM protein as-purified, pipetted into an iron-free quartz EPR tube, and flashfrozen in liquid nitrogen. Ferrous samples involved 200 µL of 400 µM enzyme
and reduced anaerobically in the presence of 0.3 molar equivalents of methyl
viologen and excess sodium dithionite.
Crystal structure of substrate-free P450sky
The as-purified enzyme was diluted to a 5 mg/mL concentration for use in
the crystallography wells. The mother-liquor consists of 225 mM ammonium
chloride, 20% PEG 6000 and drops were set up using a hanging-drop method
with 2 µL mother-liquor followed by the addition of 2 µL of protein. The trays
were then stored at 25oC with crystals forming after an average of 7 days in the
form of thick plates approximately 500 µm in length. The crystals were incubated
in 25% glycerol as a cryo-protectant and flash-frozen in liquid nitrogen for
shipping to SER-CAT at the Argonne National Laboratory. Data were collected
on beamline 22ID using a 1 second exposure time per frame. A total of 180
frames were collected and used for data reduction. The diffraction images were
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integrated by Dr. Lesa Offermann, whom also performed molecular replacement
on the data using a previously solved P450sky structure (PDBID: 4L0E) as a
template. The process of structure refinement was carried out with winCOOT
and Phenix 45.

2.3 RESULTS
Small ligand binding of P450 sky
The purified protein exhibits a Soret maximum at 417 nm (Figure 2.1),
typical of low-spin P450s 23. The A 417/280 is around 1.5, indicating a pure sample
of enzyme as determined by SDS-PAGE. The extinction coefficient was
determined to be 118 mM-1cm-1 as determined by the pyridine hemochromagen
assay 46, in close agreement with the 115 mM-1cm-1 extinction coefficient
observed for some other P450s, e.g. CYP101A1 47.
The addition of small molecule ligands can gauge the accessibility of the
heme-active site of the enzyme to the outside environment. The addition of
imidazole to P450sky results in a change of the Soret maximum from 417 nm to
424 nm (Figure 2.2), which is the typical for the addition of a nitrogen-containing
ligand bound to the distal site of a thiolate-bound heme 48. The calculated K D for
imidazole is 732 μM, which is roughly two orders of magnitude larger than for
P450s that recognize and metabolize a variety of small molecules 49, 50. The K D
of P450sky in the presence of L-His-NikP1AT is 703 µM, demonstrating no
effective change in small molecule entry and binding in the pocket (Figure 2.3).
The addition of a smaller and anionic ligand, such as cyanide, also demonstrates
difficulty in accessing the active site of the protein. The Soret of the enzyme
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shifts from 417 nm to 430 nm (Figure 2.4). Fitting this spectroscopic change
results in a K D of 19.8 mM, which is around one order of magnitude higher than
prototypical P450s, such as CYP101A1 or CYP102A1 51, 52. This low affinity for
small molecules may be insightful given the necessity for an enzyme/PCP
complex for amino acid hydroxylation. It is possible that, in the absence of Tdomain binding, that access through the active-site channel is restricted.
SEC profiles for the P450sky/L-His-NikP1AT complex
A complex is formed between P450 sky and the loaded NikP1AT didomain,
with elution peaks for P450sky at 58 mins, L-His-NikP1AT at 54 mins, and the
complex at 48 mins, which generates a shoulder that pre-elutes with the AT
domain. However, the additive molecular weight of the complex is off the column
is smaller than what is calculated. The elution profile resembles the timing for
the P450nikQ/apo-NikP1AT complex rather than the P450nikQ/L-His-NikP1AT
complex. This suggests that P450sky is either interacting with the A-domain in a
non-catalytic manner reminiscent of the P450nikQ/apo-NikP1AT interaction or
this method of binding inherently favors a different geometry with the complex.
As previously mentioned, there is no change in the spin-state with L-His-NikP1AT
when incubated with P450sky, so the complex may not be catalytically relevant
due to the lack of any interaction with the T-domain (Figure 2.5).
Binding of P450sky with apo-PCP Tyr7
There appears to be no binding between the apo-PCP Tyr7 and P450sky.
This may be due to multiple factors, including that the T-domain is still attached
to the GST solubility tag or, as mentioned earlier, an inability for T-domain
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binding in a form other than the aminoacylated state. However, the ability for SfP
to recognize the core of the protein in order to transfer the PPant to the serine
residue shows that the serine’s surrounding residues are available for
recognition. Aside from solubility issues stemming from cleavage of the solubility
tag from the T-domain, there is difficulty discerning between 50 kDa and 60 kDa
on an S-200 SEC column and facilitates the necessity for a larger tag in order to
notice the difference between the bound and unbound forms of P450sky. The
inability to bind to the apo T-domain suggests that there may be non-catalytic
binding with the A-domain of the aminoacylated NikP1AT didomain and that the
A-domain provides some level of recruitment for the P450 after the transfer of the
PPant by the pathway’s native phosphopantetheinyl transferase. This also
supports observations made with the nikkomycin system, which demonstrates no
complex formation between P450nikQ and the holo-didomain (possibly due to a
different modular conformation), but some type of complex formation with the
apo- and aminoacylated-didomain.
The addition of excess L-His-NikP1AT to P450sky does not exhibit any
recognizable optical changes. For example, no shift from a low-spin to high-spin
state is observed, which P450sky undergoes with native T-domains if loaded with
the cognate amino acid substrate 21. This may be due to the enzyme not binding
in a catalytically relevant way but also may be that P450sky does not acquire a
spin-shift with histidine. The three residues that are natively metabolized
(phenylalanine, O-methyltyrosine, and leucine) are not charged, so it is unknown
how the effects of a weakly basic residue will affect the substrate entry into the
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active site and/or how it is oriented in the distal pocket. An array of free amino
and fatty acids, of which included L-tyrosine, L-tryptophan, L-leucine, L-glycine,
L-β-alanine, L-methionine, and L-histidine were added in >100-fold excess and
results in no spin-shift regardless of the polarity or shape of the molecule (Figure
2.6). This is confirmed by the works of Cryle and Walsh that only a loaded Tdomain, possibly specific to the skyllamycin pathway, will cause a spin-shift and
subsequent catalysis by the enzyme.
Optical Characterization of P450sky
In order to quantify how much P450 enzyme is in an actively useful form is
generally determined through the binding of a hard ligand, such as the spectrum
in Figure 2.1 showing the ferrous-CO complex. The dissociation constant for CO
to P450 enzymes are in the low nanomolar range and the k off is extremely slow
53-55

. Upon binding, the Soret band of P450sky shifts from 417 nm to 450 nm,

with approximately 80% of the enzyme successfully completing this transition.
The Qx and Qy components of the Q-bands merge into one broad peak,
indicative of the presence of an intact thiolate ligand 49, 56, 57. However, unlike
CYP101A1 which maintains a stable P450 spectrum, the 450 nm spectrum
quickly decays with the Soret band transitioning to 420 nm, indicating a
displacement of the iron-thiolate ligand. This is similar to P450nikQ, which
quickly achieves an 85% transition of the Soret to 450 nm and quickly depletes.
This may also indicate that more enzyme is active, but the initial spectrum is
unable to be ascertained due to the time between the addition of sodium
dithionite and the initialization of the first spectrum on the UV-Vis.
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The fully reduced spectrum in Figure 2.1 displays a Soret shift from 417
nm to 410 nm, which is similarly observed in other P450s as well as P450nikQ 58,
59

. The ferrous form of the enzyme is, as expected, highly sensitive to the

presence of molecular oxygen, with the Soret immediately shifting from 410 nm
back to its ferric location at 417 nm. However, when the formation of the ferrousoxy complex was observed (Figure 2.7), the wavelength of the Soret remained at
417 nm, but with a greatly reduced extinction coefficient reminiscent of human
cytochrome P450 3A4 60, which is also observed to have a redox potential lower
than average at -200 mV in a similar spin-state 61. This differs from most P450s,
which shows a shift in the Soret band to the vicinity of 430-435 nm, as is also the
case with P450nikQ 58, 62. Therefore, this may be a normal occurrence for P450s
with unusually low redox potentials. In addition to the decreased 417 nm
extinction coefficient for the reduced species, the rate of autoxidation is also
several orders of magnitude greater than with most other p450s 60, 63-65, with a
ferrous-oxy decay rate of 147 s-1. It is currently unknown why the rate of ferrousoxy autoxidation is high in P450sky compared to other P450 enzymes.
Electronic Paramagnetic Resonance spectroscopy of P450sky
P450sky shows a clean S=1/2 signal indicative of a ferric P450 as-purified,
with g-values of 2.42, 2.24, and 1.92 (Figure 2.7). These are expected in
unbound, low-spin P450 enzymes 66-69. However, there is a small shoulder
attached to the g z signal that has a value of 2.48, but could be due to the
presence of imidazole that remained following dialysis 70, 71. There are also
peaks at 2.04 and 2.00 indicative of a contaminant copper(II) signal present
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within the cavity at the time of data collection and not due to its presence in the
sample itself 72. Unfortunately, there is no data concerning the bound P450sky/LHis-NikP1AT complex available at this time. Should there be a shift in the gvalues, then it would be likely that the substrate is present in the active site, with
the histidine residue ligating to the heme.

2.4 DISCUSSION
Multiple NRPS systems have been studied in the context of their own
operon products, such as the P450-based β-hydroxylation chemistry performed
by the nikkomycin system 18, 24, the diiron monooxygenase β-hydroxylation
chemistry performed by the chloramphenicol system 17, as well as P450-based
aryl crosslinking reactions for the vancomycin-derived antibiotics 73-75. While the
study of these as closed systems has reached its pinnacle, there is untapped
potential concerning the cross-reactivity of exogenous enzymes to their nonnative NRPS counterparts. These studies involving individual components of
various systems would be ideal since each system may have issues concerning
solubility, expression, or rarity of substrate that may prohibit the study of these
systems in vitro or in vivo due to the cost necessary to work around these issues.
One potential issue preventing the immediate use of these types of systems is
the unknown compatibility and recognition between components of two different
systems. However, the idea of combining components from homologous
systems with similar enzymes or chemistries may prove to be a good starting
point for future research.
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The identification of a homologous pair of systems became the primary
priority, with emphasis on systems that perform the same chemistry. In this
case, both the skyllamycin and nikkomycin pathways work with P450 enzymes
that utilize the canonical mechanism associated with CYP101A1, by
hydroxylating their respective amino acids at the β-carbon and maintaining a
reliance on redox partners for 1+1 electron transfer 76. The two P450s share a
34% identity and a 53% similarity, so they share a high enough likeness to each
other that they can be used in this experiment (EMBOSS needle alignment).
While the P450s are homologous, the NRPS systems are not, as P450sky works
with three different modules incorporated in multi-modular NRPS and P450 nikQ
operates with a unimodular NRPS. However, this difference in NRPS structure
provides an advantage, as the NikP1 gene is a single, soluble protein that
contains only a di-domain for the module instead of three or more that are
present in each protein for Sky30-32. Unfortunately, since the residues
necessary for complex recognition are unknown for both systems, the surfaces of
the two P450s cannot be properly compared for compatibility.
Several notable points have been made by Wise et al. concerning the
behavior of the nikkomycin system. For instance, SEC elution profiles show that
the unbound apo- and L-His-NikP1AT elute at the same point in time while the
holo-NRPS elutes at a later time point. P450nikQ was demonstrated to interact
with NikP1AT if the NRPS is in either its apo or aminoacylated form. However, it
was noted that there appears to be two forms of this interaction, with the
P450 nikQ /apo-NikP1AT complex eluting from an S-200 size exclusion column
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later and at a smaller calculated molecular weight than expected compared to
P450nikQ/L-His-NikP1AT (Figure 2.8), which elutes at the properly calculated
molecular weight. P450nikQ shows no apparent affinity for holo-NikP1AT, but
this is justified with the different elution pattern from unbound holo-NikP1AT in
comparison to apo- and L-His-NikP1AT. There is currently no evidence
suggesting whether the same binding pattern would apply with P450nikQ to the
apo-, holo-, or aminoacylated-PCP domain.
Work presented by Ullmann and Cryle on the skyllamycin system have
demonstrated a lack of affinity between the P450 and the apo- or holo-PCP
domain 36. There is data that compares the binding of the P450 with its three
associated PCPs that have been aminoacylated with various hydrophobic and
bulky amino acids, as well as enantiomers of the recognized amino acids for
each T-domain 21. The results show that the tethered amino acid does alter the
recognition of the hydroxylase with the T-domain to some degree, demonstrating
that the amino acid to some extent assists targeting by the hydroxylase to the
NRPS to form a β-hydroxylation product, which may be involved in downstream
processes like an intramolecular Fischer condensation-leading to a
pharmacologically-active depsipeptide.
Comparison of these points may assist in explaining the results of the
chromatogram between P450sky and L-His-NikP1AT (Figure 2.9). For instance,
the similarity in the elution profiles compared to P450nikQ and apo-NRPS may
suggest that the PCP is not the sole force in the recognition motif, assuming that
the apo-NRPS is still in a position that is favorable to receive a PPant, rather than
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binding to the hydroxylase and preventing the ability to become catalytically
relevant. In addition, histidine, a weakly basic amino acid, is not tethered to any
of the PCPs that are recognized by P450sky, which prefers hydrophobic or
neutral amino acids 21. The method of entry for the tethered amino acid through
the channel of the P450 is currently unknown and inhibits our knowledge
concerning the importance of amino acid recognition. Therefore, the T-domain
may not be interacting with the hydroxylase, which would also support the lack of
an observable spin-shift upon the addition of excess NRPS to P450sky. It would
be interesting to observe the effect of transplanting one of the PCP domains
associated with the skyllamycin pathway in the place of the PCP attached to
NikP1AT and again run SEC to see if the elution of the complex occurs at a
similar place as with P450nikQ/L-His-NikP1AT.
The maintenance of the P450nikQ/NikP1 complex in the presence of
high salt has been determined to be driven predominantly by hydrophobic forces.
So, in the homologous P450sky/NikP1 system, it may be inferred that the
interaction is also driven by hydrophobic forces. Granted, the concentration of
sodium chloride during the SEC run is 150mM, compared to the 500mM present
with the P450nikQ interaction, but the evidence that the exterior of the protein
have a similar charge density gives credence that the interaction of P450sky with
NikP1 is driven by hydrophobicity. The interaction between CmlA and CmlP,
albeit a different system with different tertiary and quaternary structure for the
hydroxylase, do not maintain a complex throughout an SEC run. There is also
no sign of a complex with the use of a native-PAGE gel either. This could allude
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to a greater variety of interaction events between systems concerning a mixed
use of electrostatic or hydrophobic forces driving the interaction.

2.5 CONCLUSION
In summary, P450sky is a homolog of P450nikQ and behaves in a similar
manner, with substrate recognition dependent on attachment to a recognized
PCP domain. P450sky from the skyllamycin pathway is demonstrated to interact
with the NRPS di-domain from the nikkomycin pathway, a cross-system
interaction that may prove interesting when designing custom NRPS biosynthetic
pathways. However, the interaction does not appear to create a P450sky/L-HisNikP1AT complex that is catalytically relevant. This is most likely due to the
hydroxylase interacting with the A-domain, but with little or no recognition for the
PCP domain of the NikP1 module. The mode of binding, whether hydrophobic or
electrostatic, is unknown, but similarity between the two hydroxylases may infer
that the interaction between P450sky and NikP1 may also be hydrophobic. The
future direction of this project would transplant a hydroxylated PCP from the
skyllamycin into the nikkomycin NRPS and test for functionality, either with SEC
or through substrate turnover experiments.

2.6 REFERENCES
[1] Reimmann, C., Patel, H. M., Serino, L., Barone, M., Walsh, C. T., and Haas,
D. (2001) Essential PchG-dependent reduction in pyochelin biosynthesis
of Pseudomonas aeruginosa, J Bacteriol 183, 813-820.
[2] O'Brien, D. P., Kirkpatrick, P. N., O'Brien, S. W., Staroske, T., Richardson, T.
I., Evans, D. A., Hopkinson, A., Spencer, J. B., and Williams, D. H. (2000)
69

Expression and assay of an N-methyltransferase involved in the
biosynthesis of a vancomycin group antibiotic, Chem Commun, 103-104.
[3] Stachelhaus, T., and Walsh, C. T. (2000) Mutational analysis of the
epimerization domain in the initiation module PheATE of gramicidin S
synthetase, Biochemistry-Us 39, 5775-5787.
[4] Linne, U., and Marahiel, M. A. (2000) Control of directionality in nonribosomal
peptide synthesis: role of the condensation domain in preventing
misinitiation and timing of epimerization, Biochemistry-Us 39, 1043910447.
[5] Chen, H., and Walsh, C. T. (2001) Coumarin formation in novobiocin
biosynthesis: beta-hydroxylation of the aminoacyl enzyme tyrosyl-S-NovH
by a cytochrome P450 NovI, Chem Biol 8, 301-312.
[6] Miller, D. A., and Walsh, C. T. (2001) Yersiniabactin synthetase: probing the
recognition of carrier protein domains by the catalytic heterocyclization
domains, Cy1 and Cy2, in the chain-initiating HWMP2 subunit,
Biochemistry-Us 40, 5313-5321.
[7] Walsh, C. T., Chen, H. W., Keating, T. A., Hubbard, B. K., Losey, H. C., Luo,
L. S., Marshall, C. G., Miller, D. A., and Patel, H. M. (2001) Tailoring
enzymes that modify nonribosomal peptides during and after chain
elongation on NRPS assembly lines, Curr Opin Chem Biol 5, 525-534.
[8] Pohle, S., Appelt, C., Roux, M., Fiedler, H. P., and Sussmuth, R. D. (2011)
Biosynthetic gene cluster of the non-ribosomally synthesized

70

cyclodepsipeptide skyllamycin: deciphering unprecedented ways of
unusual hydroxylation reactions, J Am Chem Soc 133, 6194-6205.
[9] Wright, G. D. (2003) Mechanisms of resistance to antibiotics, Curr Opin Chem
Biol 7, 563-569.
[10] Aharonowitz, Y., and Friedrich, C. G. (1980) Alanine dehydrogenase of the
beta-lactam antibiotic producer Streptomyces clavuligerus, Arch Microbiol
125, 137-142.
[11] Hoehn, P., Ghisalba, O., Moerker, T., and Peter, H. H. (1995) 3'-Demethoxy3'-hydroxystaurosporine, a novel staurosporine analogue produced by a
blocked mutant, J Antibiot (Tokyo) 48, 300-305.
[12] Billich, A., and Zocher, R. (1987) N-Methyltransferase Function of the
Multifunctional Enzyme Enniatin Synthetase, Biochemistry-Us 26, 84178423.
[13] Tercero, J. A., Espinosa, J. C., Lacalle, R. A., and Jimenez, A. (1996) The
biosynthetic pathway of the aminonucleoside antibiotic puromycin, as
deduced from the molecular analysis of the pur cluster of Streptomyces
alboniger, J Biol Chem 271, 1579-1590.
[14] Davies, J., and Wright, G. D. (1997) Bacterial resistance to aminoglycoside
antibiotics, Trends Microbiol 5, 234-240.
[15] Wright, G. D. (2005) Bacterial resistance to antibiotics: enzymatic
degradation and modification, Adv Drug Deliv Rev 57, 1451-1470.
[16] Long, K. S., Poehlsgaard, J., Kehrenberg, C., Schwarz, S., and Vester, B.
(2006) The Cfr rRNA methyltransferase confers resistance to Phenicols,

71

Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin A
antibiotics, Antimicrob Agents Chemother 50, 2500-2505.
[17] Makris, T. M., Chakrabarti, M., Munck, E., and Lipscomb, J. D. (2010) A
family of diiron monooxygenases catalyzing amino acid beta-hydroxylation
in antibiotic biosynthesis, Proc Natl Acad Sci U S A 107, 15391-15396.
[18] Chen, H., Hubbard, B. K., O'Connor, S. E., and Walsh, C. T. (2002)
Formation of beta-hydroxy histidine in the biosynthesis of nikkomycin
antibiotics, Chem Biol 9, 103-112.
[19] Mootz, H. D., Schwarzer, D., and Marahiel, M. A. (2000) Construction of
hybrid peptide synthetases by module and domain fusions, Proc Natl Acad
Sci U S A 97, 5848-5853.
[20] Schneider, A., Stachelhaus, T., and Marahiel, M. A. (1998) Targeted
alteration of the substrate specificity of peptide synthetases by rational
module swapping, Mol Gen Genet 257, 308-318.
[21] Uhlmann, S., Sussmuth, R. D., and Cryle, M. J. (2013) Cytochrome p450sky
interacts directly with the nonribosomal peptide synthetase to generate
three amino acid precursors in skyllamycin biosynthesis, ACS Chem Biol
8, 2586-2596.
[22] Haslinger, K., Brieke, C., Uhlmann, S., Sieverling, L., Sussmuth, R. D., and
Cryle, M. J. (2014) The structure of a transient complex of a nonribosomal
peptide synthetase and a cytochrome P450 monooxygenase, Angew
Chem Int Ed Engl 53, 8518-8522.

72

[23] Schenkman, J. B., and Jansson, I. (2006) Spectral analyses of cytochromes
P450, Methods Mol Biol 320, 11-18.
[24] Wise, C. E., and Makris, T. M. (2017) Recruitment and Regulation of the
Non-ribosomal Peptide Synthetase Modifying Cytochrome P450 Involved
in Nikkomycin Biosynthesis, ACS Chem Biol 12, 1316-1326.
[25] Lewis, D. F. V., and Hlavica, P. (2000) Interactions between redox partners
in various cytochrome P450 systems: functional and structural aspects,
Bba-Bioenergetics 1460, 353-374.
[26] Guenzi, E., Galli, G., Grgurina, I., Gross, D. C., and Grandi, G. (1998)
Characterization of the syringomycin synthetase gene cluster. A link
between prokaryotic and eukaryotic peptide synthetases, J Biol Chem
273, 32857-32863.
[27] Finking, R., and Marahiel, M. A. (2004) Biosynthesis of nonribosomal
peptides, Annu Rev Microbiol 58, 453-488.
[28] Stachelhaus, T., Mootz, H. D., and Marahiel, M. A. (1999) The specificityconferring code of adenylation domains in nonribosomal peptide
synthetases, Chem. Biol. 6, 493-505.
[29] Belshaw, P. J., Walsh, C. T., and Stachelhaus, T. (1999) Aminoacyl-CoAs as
probes of condensation domain selectivity in nonribosomal peptide
synthesis, Science 284, 486-489.
[30] Ackerley, D. F., Caradoc-Davies, T. T., and Lamont, I. L. (2003) Substrate
specificity of the nonribosomal peptide synthetase PvdD from
Pseudomonas aeruginosa, J Bacteriol 185, 2848-2855.

73

[31] Winn, M., Fyans, J. K., Zhuo, Y., and Micklefield, J. (2016) Recent advances
in engineering nonribosomal peptide assembly lines, Nat Prod Rep 33,
317-347.
[32] Clugston, S. L., Sieber, S. A., Marahiel, M. A., and Walsh, C. T. (2003)
Chirality of peptide bond-forming condensation domains in nonribosomal
peptide synthetases: the C5 domain of tyrocidine synthetase is a (D)C(L)
catalyst, Biochemistry-Us 42, 12095-12104.
[33] Kohli, R. M., Takagi, J., and Walsh, C. T. (2002) The thioesterase domain
from a nonribosomal peptide synthetase as a cyclization catalyst for
integrin binding peptides, Proc Natl Acad Sci U S A 99, 1247-1252.
[34] Trauger, J. W., Kohli, R. M., and Walsh, C. T. (2001) Cyclization of
backbone-substituted peptides catalyzed by the thioesterase domain from
the tyrocidine nonribosomal peptide synthetase, Biochemistry-Us 40,
7092-7098.
[35] Reimer, J. M., Aloise, M. N., Harrison, P. M., and Schmeing, T. M. (2016)
Synthetic cycle of the initiation module of a formylating nonribosomal
peptide synthetase, Nature 529, 239-242.
[36] Kokona, B., Winesett, E. S., von Krusenstiern, A. N., Cryle, M. J., Fairman,
R., and Charkoudian, L. K. (2016) Probing the selectivity of betahydroxylation reactions in non-ribosomal peptide synthesis using
analytical ultracentrifugation, Anal Biochem 495, 42-51.

74

[37] Blatti, J. L., Beld, J., Behnke, C. A., Mendez, M., Mayfield, S. P., and
Burkart, M. D. (2012) Manipulating fatty acid biosynthesis in microalgae
for biofuel through protein-protein interactions, PLoS One 7, e42949.
[38] Vance, S., Tkachenko, O., Thomas, B., Bassuni, M., Hong, H., Nietlispach,
D., and Broadhurst, W. (2016) Sticky swinging arm dynamics: studies of
an acyl carrier protein domain from the mycolactone polyketide synthase,
Biochem J 473, 1097-1110.
[39] Nguyen, C., Haushalter, R. W., Lee, D. J., Markwick, P. R., Bruegger, J.,
Caldara-Festin, G., Finzel, K., Jackson, D. R., Ishikawa, F., O'Dowd, B.,
McCammon, J. A., Opella, S. J., Tsai, S. C., and Burkart, M. D. (2014)
Trapping the dynamic acyl carrier protein in fatty acid biosynthesis, Nature
505, 427-431.
[40] Lelyveld, V. S., Brustad, E., Arnold, F. H., and Jasanoff, A. (2011) MetalSubstituted Protein MRI Contrast Agents Engineered for Enhanced
Relaxivity and Ligand Sensitivity, J Am Chem Soc 133, 649-651.
[41] Costa, S. J., Coelho, E., Franco, L., Almeida, A., Castro, A., and Domingues,
L. (2013) The Fh8 tag: a fusion partner for simple and cost-effective
protein purification in Escherichia coli, Protein Expr Purif 92, 163-170.
[42] Goldman, S., Kim, R., Hung, L. W., Jancarik, J., and Kim, S. H. (1998)
Purification, crystallization and preliminary X-ray crystallographic analysis
of Pyrococcus furiosus DNA polymerase, Acta Crystallogr D Biol
Crystallogr 54, 986-988.

75

[43] La Clair, J. J., Foley, T. L., Schegg, T. R., Regan, C. M., and Burkart, M. D.
(2004) Manipulation of carrier proteins in antibiotic biosynthesis, Chem
Biol 11, 195-201.
[44] Huang, Q., Zhou, X. L., Hu, Q. H., Lei, H. Y., Fang, Z. P., Yao, P., and
Wang, E. D. (2014) A bridge between the aminoacylation and editing
domains of leucyl-tRNA synthetase is crucial for its synthetic activity, Rna
20, 1440-1450.
[45] Adams, P. D., Afonine, P. V., Bunkoczi, G., Chen, V. B., Davis, I. W., Echols,
N., Headd, J. J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W.,
McCoy, A. J., Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C.,
Richardson, J. S., Terwilliger, T. C., and Zwart, P. H. (2010) PHENIX: a
comprehensive Python-based system for macromolecular structure
solution, Acta Crystallogr D Biol Crystallogr 66, 213-221.
[46] Barr, I., and Guo, F. (2015) Pyridine Hemochromagen Assay for Determining
the Concentration of Heme in Purified Protein Solutions, Bio Protoc 5.
[47] Gunsalus, I. C., and Wagner, G. C. (1978) Bacterial P-450cam methylene
monooxygenase components: cytochrome m, putidaredoxin, and
putidaredoxin reductase, Methods Enzymol 52, 166-188.
[48] Dawson, J. H., Andersson, L. A., and Sono, M. (1982) Spectroscopic
investigations of ferric cytochrome P-450-CAM ligand complexes.
Identification of the ligand trans to cysteinate in the native enzyme, J Biol
Chem 257, 3606-3617.

76

[49] Bui, S. H., McLean, K. J., Cheesman, M. R., Bradley, J. M., Rigby, S. E.,
Levy, C. W., Leys, D., and Munro, A. W. (2012) Unusual spectroscopic
and ligand binding properties of the cytochrome P450-flavodoxin fusion
enzyme XplA, J Biol Chem 287, 19699-19714.
[50] Muralidhara, B. K., Negi, S., Chin, C. C., Braun, W., and Halpert, J. R.
(2006) Conformational flexibility of mammalian cytochrome P450 2B4 in
binding imidazole inhibitors with different ring chemistry and side chains.
Solution thermodynamics and molecular modeling, J Biol Chem 281,
8051-8061.
[51] Sono, M., and Dawson, J. H. (1982) Formation of Low-Spin Complexes of
Ferric Cytochrome P-450-Cam with Anionic Ligands - Spin State and
Ligand Affinity Comparison to Myoglobin, J Biol Chem 257, 5496-5502.
[52] Girvan, H. M., Levy, C. W., Williams, P., Fisher, K., Cheesman, M. R., Rigby,
S. E., Leys, D., and Munro, A. W. (2010) Glutamate-haem ester bond
formation is disfavoured in flavocytochrome P450 BM3: characterization of
glutamate substitution mutants at the haem site of P450 BM3, Biochem J
427, 455-466.
[53] Debey, P., Balny, C., and Douzou, P. (1973) Low temperature studies of
microsomal cytochrome P450 flash photolysis experiments, FEBS Lett 35,
86-90.
[54] Gray, R. D. (1982) Kinetics and mechanism of carbon monoxide binding to
purified liver microsomal cytochrome P-450 isozymes, J Biol Chem 257,
1086-1094.

77

[55] Oertle, M., Richter, C., Winterhalter, K. H., and Di Iorio, E. E. (1985) Kinetics
of carbon monoxide binding to phenobarbital-induced cytochrome P-450
from rat liver microsomes: a simple bimolecular process, Proc Natl Acad
Sci U S A 82, 4900-4904.
[56] Chenge, J. T., Duyet, L. V., Swami, S., McLean, K. J., Kavanagh, M. E.,
Coyne, A. G., Rigby, S. E. J., Cheesman, M. R., Girvan, H. M., Levy, C.
W., Rupp, B., von Kries, J. P., Abell, C., Leys, D., and Munro, A. W.
(2017) Structural Characterization and Ligand/Inhibitor Identification
Provide Functional Insights into the Mycobacterium tuberculosis
Cytochrome P450 CYP126A1, J Biol Chem 292, 1310-1329.
[57] McLean, K. J., Warman, A. J., Seward, H. E., Marshall, K. R., Girvan, H. M.,
Cheesman, M. R., Waterman, M. R., and Munro, A. W. (2006) Biophysical
characterization of the sterol demethylase P450 from Mycobacterium
tuberculosis, its cognate ferredoxin, and their interactions, Biochemistry
45, 8427-8443.
[58] Luthra, A., Denisov, I. G., and Sligar, S. G. (2011) Spectroscopic features of
cytochrome P450 reaction intermediates, Arch Biochem Biophys 507, 2635.
[59] Egawa, T., Hishiki, T., Ichikawa, Y., Kanamori, Y., Shimada, H., Takahashi,
S., Kitagawa, T., and Ishimura, Y. (2004) Refolding processes of
cytochrome P450cam from ferric and ferrous acid forms to the native
conformation. Formations of folding intermediates with non-native heme
coordination state, J Biol Chem 279, 32008-32017.

78

[60] Denisov, I. G., Grinkova, Y. V., Baas, B. J., and Sligar, S. G. (2006) The
ferrous-dioxygen intermediate in human cytochrome P450 3A4. Substrate
dependence of formation and decay kinetics, J Biol Chem 281, 2331323318.
[61] Das, A., Grinkova, Y. V., and Sligar, S. G. (2007) Redox potential control by
drug binding to cytochrome P450 3A4, J Am Chem Soc 129, 1377813779.
[62] Couture, M., Stuehr, D. J., and Rousseau, D. L. (2000) The ferrous dioxygen
complex of the oxygenase domain of neuronal nitric-oxide synthase, J Biol
Chem 275, 3201-3205.
[63] Grinkova, Y. V., Denisov, I. G., Waterman, M. R., Arase, M., Kagawa, N.,
and Sligar, S. G. (2008) The ferrous-oxy complex of human aromatase,
Biochem Biophys Res Commun 372, 379-382.
[64] Ost, T. W., Clark, J., Mowat, C. G., Miles, C. S., Walkinshaw, M. D., Reid, G.
A., Chapman, S. K., and Daff, S. (2003) Oxygen activation and electron
transfer in flavocytochrome P450 BM3, J Am Chem Soc 125, 1501015020.
[65] Zhang, H., Gruenke, L., Arscott, D., Shen, A., Kasper, C., Harris, D. L.,
Glavanovich, M., Johnson, R., and Waskell, L. (2003) Determination of the
rate of reduction of oxyferrous cytochrome P450 2B4 by 5-deazariboflavin
adenine dinucleotide T491V cytochrome P450 reductase, Biochemistry-Us
42, 11594-11603.

79

[66] Peisach, J., and Blumberg, W. E. (1970) Electron paramagnetic resonance
study of the high- and low-spin forms of cytochrome P-450 in liver and in
liver microsomes from a methylcholanthrene-treated rabbit, Proc Natl
Acad Sci U S A 67, 172-179.
[67] Tsai, R., Yu, C. A., Gunsalus, I. C., Peisach, J., Blumberg, W., OrmeJohnson, W. H., and Beinert, H. (1970) Spin-state changes in cytochrome
P-450cam on binding of specific substrates, Proc Natl Acad Sci U S A 66,
1157-1163.
[68] Kumaki, K., Sato, M., Kon, H., and Nebert, D. W. (1978) Correlation of type I,
type II, and reverse type I difference spectra with absolute changes in spin
state of hepatic microsomal cytochrome P-450 iron from five mammalian
species, J Biol Chem 253, 1048-1058.
[69] Davydov, R., Im, S., Shanmugam, M., Gunderson, W. A., Pearl, N. M.,
Hoffman, B. M., and Waskell, L. (2016) Role of the Proximal Cysteine
Hydrogen Bonding Interaction in Cytochrome P450 2B4 Studied by
Cryoreduction, Electron Paramagnetic Resonance, and Electron-Nuclear
Double Resonance Spectroscopy, Biochemistry-Us 55, 869-883.
[70] Morita, H., Yoshikawa, H., Takizawa, T., Shirai, M., Akahori, F., and
Yoshimura, T. (2006) The formation of g=2.49-species of cytochrome
P450 in the rat liver by PCB126 oral administration: identification of heme
axial ligands by EPR spectroscopy, Biosci Biotechnol Biochem 70, 29742981.

80

[71] Conner, K. P., Cruce, A. A., Krzyaniak, M. D., Schimpf, A. M., Frank, D. J.,
Ortiz de Montellano, P., Atkins, W. M., and Bowman, M. K. (2015) Drug
modulation of water-heme interactions in low-spin P450 complexes of
CYP2C9d and CYP125A1, Biochemistry-Us 54, 1198-1207.
[72] Chandra, S., and Sangeetika, X. (2004) EPR, magnetic and spectral studies
of copper(II) and nickel(II) complexes of schiff base macrocyclic ligand
derived from thiosemicarbazide and glyoxal, Spectrochim Acta A Mol
Biomol Spectrosc 60, 147-153.
[73] Woithe, K., Geib, N., Zerbe, K., Li, D. B., Heck, M., Fournier-Rousset, S.,
Meyer, O., Vitali, F., Matoba, N., Abou-Hadeed, K., and Robinson, J. A.
(2007) Oxidative phenol coupling reactions catalyzed by OxyB: a
cytochrome P450 from the vancomycin producing organism. implications
for vancomycin biosynthesis, J Am Chem Soc 129, 6887-6895.
[74] Cryle, M. J., Meinhart, A., and Schlichting, I. (2010) Structural
characterization of OxyD, a cytochrome P450 involved in betahydroxytyrosine formation in vancomycin biosynthesis, J Biol Chem 285,
24562-24574.
[75] Peschke, M., Brieke, C., and Cryle, M. J. (2016) F-O-G Ring Formation in
Glycopeptide Antibiotic Biosynthesis is Catalysed by OxyE, Sci Rep 6,
35584.
[76] Holden, M., Mayhew, M., Bunk, D., Roitberg, A., and Vilker, V. (1997)
Probing the interactions of putidaredoxin with redox partners in camphor

81

P450 5-monooxygenase by mutagenesis of surface residues, J Biol Chem
272, 21720-21725.

82

Figures

Figure 2.1: Optical characterization of P450sky. 5 µM of enzyme is
present for the ferric (black), ferrous (red), and ferrous-CO (blue) complex of
P450sky. The ferrous species was determined with 0.3 molar equivalents of
methyl viologen (shown as a shoulder at 395 nm) and excess sodium dithionite.
The ferrous-CO species was taken with the addition of CO to anaerobic ferric
enzyme with methyl viologen and the addition of excess sodium dithionite.

Figure 2.2: Determination of the KD of imidazole through the optical
change of the Soret of P450sky. The dissociation constant was determined
using 4.5 µM of unbound P450sky. Fitting the shift in the spectrum from 417 nm
to 424 nm with a Michaelis-Menten plot gives a K D = 732 µm. This suggests that
the channel to the active site of the enzyme is closed to small molecule ligands
when unbound to recognized T-domain.
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Figure 2.3: Determination of the K D of imidazole in the presence of
P450sky and L-his-NikP1AT through the optical change of the Soret of P450sky.
The dissociation constant determined with the 5 µM P450sky and 50 µM L-HisNikP1AT, as in Figure 2. There is negligible change in the K D , suggesting the
lack of binding to the P450 to the T-domain of the NRPS.

Figure 2.4: Determination of the K D of cyanide through the optical change
of the Soret of P450sky. The dissociation constant was calculated with 4.5 µM of
non-NRPS bound P450sky. The shift from 417 nm to 430 nm is expected for the
binding of a carbon ligand to the porphyrin. The high K D = 18.9 mM suggests the
channel of the active site is both closed and/or does not prefer anionic charges
entering guiding the entrance into the channel. A spectrum of a cyanide titration
in the presence of NRPS-bound P450sky was not taken.
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Figure 2.5: Optical spectra of P450sky and P450sky in the presence of Lhis-NikP1AT. Overlay shows 5 µM P450sky without (black) and bound (red) to
75 µM L-his-NikP1AT. Note the lack of high-spin formation at 392 nm and static
Q-bands from 500-600 nm.
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Figure 2.6: Optical spectra of P450sky with amino acids. The profiles
show 4.5 µM – 5 µM P450sky incubated with at least >100-fold free amino acids.
Note the lack of spin-shift in the Soret maximum, indicating that free amino acid
either not entering the active site or is not displacing the water ligand from the
porphyrin of the enzyme.
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Figure 2.7: Decay of the P450sky oxy complex. The complex was
formed with 5 µM ferrous P450sky mixed with 1 mM molecular oxygen on the
Stopped-flow. There is no hyspochromic shift generally observed with formation
of a ferrous-oxy complex, usually present in the the 430-440 nm range. In
contrast, the extinction coefficient decreases with no shift in the Soret. The Qbands split from a single peak back to the two recognized in the ferric spectrum.
The rate of autoxidation more quickly than in other P450s.
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Figure 2.8: EPR of ferric, low-spin P450sky. The spectrum shows 400
µM unbound P450sky using X-band EPR. The g-values align with other P450
spectra in a low-spin state. Peaks between 3250 and 3350 gauss are products
of a copper contaminant in the cavity of the instrument.
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Figure 2.9: Size-exclusion chromatograph of the P450nikQ/L-hisNikP1AT complex. The profiles show P450nikQ (black) and the P450nikQ/L-HisNikP1AT complex (red) at a 1:10 mixture. The elution peak at 48 minutes is
around 125 kDa. The elution peak at 58 minutes represents is around 50 kDa,
representative of the presence of free P450. The decrease in the 417/280 nm
ratio at 48 minutes for the complex is due to the aromatics present in the NRPS
that is co-eluting with the P450. The absorbance increases for the ratio at 58
minutes, which is the ratio observed with purified P450nikQ.
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Figure 2.10: Size-exclusion chromatograph of the P450nikQ/L-hisNikP1AT complex. The profiles show P450sky (black) and the P450sky/L-HisNikP1AT complex (red) at a 1:10 ratio. The complex elutes at 49.5 minutes,
coinciding with 105 kDa and is similar to the behavior of the complex between
P450nikQ and L-His-NikP1AT. Unbound P450sky elutes at 58 minutes,
corresponding to 50 kDa.
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Figure 2.11: Chromatographic partition coefficients (K av ) of the
hydroxylase/NRPS complexes. The plot shows the K av s for the protein
standards and the corresponding hydroxylase/NRPS complexes as a function of
the log of molecular weight.

Figure 2.12: Sequence alignment for PCPs of skyllamycin and
nikkomycin pathways. PCPs natively hydroxylated by P450sky are shown in
green and with the addition of the sequence for the NikP1AT PCP in blue. The
phosphopantetheinylated serine residue is shown in red. The sequences are
similar and suggests the possibility of interactions between the NRPS and the
hydroxylase.
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Figure 2.13: Sequence alignment for P450sky and P450nikQ. The
cysteine that provides the thiolate ligand to the porphyrin is in red. The site of
interaction at the F and G helices with the T-domain are in green. There is
strong similarity in the G helix, however, more variability is present in the F helix.
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CHAPTER 3
THE SUBSTITUTION OF MANGANESE-PROTOPORPHYRIN IX INTO
CYTOCHROME P450OLET
3.1 INTRODUCTION
The incorporation of non-native porphyrin cofactors in heme enzymes
represents a powerful tool to systematically alter the chemistry, reactivity,
spectroscopic properties, or redox potential of enzymes that utilize porphyrin as a
co-factor. In its idealized form, this methodology represents a means to retain a
complex polypeptide in a native state, preserving critical features of the
secondary coordination sphere that are exquisitely tuned to enable substrate
recognition, ligand binding, and small molecule activation, among others 1-4.
Historically, many of the protocols that have aimed to substitute porphyrins in
heme-enzymes have involved harsh conditions that either partially or fully
denature the protein 5, 6. This includes the removal of the axial ligand through
protonation at low pH, and extraction of the porphyrin in a suitable organic
solvent 7. The newly-introduced porphyrin is then added to the denatured
protein, followed by careful alteration of the buffer environment to promote proper
refolding. For some proteins (e.g. globins) this procedure works reasonably well
due to the nature of the more weakly-bound axial ligand (histidine) and exposed
nature of the heme in the final folded state 8. Cytochrome P450s, on the other
hand, have been notoriously difficult proteins for heme-exchange studies due to
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stronger bonding of the iron to the axial ligand (thiolate) and the buried nature of
the heme. As a result, reconstitution studies have only reported in a handful of
studies due to the low-yield of final protein (typically ~ 5%).
Recently, a number of different strategies have explored the use of in vivo
pathways for novel heme incorporation. The Marletta laboratory has devised a
technique that utilizes the RP523 cell line for porphyrin incorporation, eliminating
the need for harsh unfolding conditions 9. To achieve this, the RP523 cell line of
E. coli was utilized which contains a knockout of the hemB, a gene that encodes
for a zinc enzyme involved in the second step in the biosynthesis of hemin and
synthesizes monopyrrole porphyobilinogen from two molecules of 5aminolevulinic acid 10-13. This inhibits the production of hemin and consequently
promotes the production of the apo-enzyme. An added advantage of this cell line
is that the cell wall and membrane are both permeable to non-native hemes that
are added to the culture medium 14. However, a drawback of this procedure is
that it requires an anaerobic culture environment due to the lack of production of
heme-enzymes such as catalase that are necessary for the detoxification of
reactive oxygen species.
Another attractive method involves the co-expression of heme
transporters that are utilized by a number of prokaryotes (including pathogenic
bacteria) for the uptake of heme. ChuA is a 69-kDa heme receptor located in
the outer membrane of E. coli O157:H7 that scavenges heme from the
surrounding environment under iron-replete conditions 15, 16. The importation of
iron ions works with the cooperation of the siderophore aerobactin and the
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siderophore importer TonB, which chelates iron and transports the metal to the
cytosol 17, 18. The mechanism for ChuA (Figure 3.1) emphasizes bypasses the
need for an iron chelator and the holo-porphyrin can be directly recognized and
imported by ChuA into the periplasmic space. Once inside the periplasmic
space, the porphyrin is shuttled to the inner membrane by the periplasmic
binding protein (PBP), an ATP-binding cassette (ABC) transport protein for
movement across the inner membrane into the cytosol 19.
When overexpressed, the ChuA protein proposedly results in a decrease
in production of native heme, leading to the incorporation of any non-native
porphyrin in the cytosol by the expressed proteins. The only detraction of using
this method is the necessity for minimal media, which acts to further decrease
the production of native Fe-Protoporphyrin IX 20. However, since the presence of
the added porphyrin can be added at high levels, there is little concern over the
incorporation of hemin into the protein of interest. The co-expression of ChuA
with a gene of interest can also result in an increase in holo-protein production
compared to normal E. coli strains that rely on the bacterial porphyrin
biosynthetic pathway due to higher concentrations of cytosolic heme 21, 22.
ChuA has been previously used to incorporate Fe-deuteroporphyrin IX into
P450BM3 as a tool to determine if the method can be applied to a thiolate-ligated
porphyrin enzyme 20. In conjunction with minimal media, there was 99 %
incorporation of the Fe-DPIX into the P450, compared to 63 % when the same
procedure was attempted in Luria Broth. Other metallo-PPIXs have been
incorporation into cytochrome c to test for effects on activity and inhibition 23.
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Although the porphyrins were transported into the cytosol, there were issues with
incorporation of zinc and tin based porphyrins into the protein, suggesting that
factors such as sterics or electronics may be important factors when attempting
to express metalloproteins in vivo. Nonetheless, the ChuA system has proven to
be a useful tool in concert with directed evolution, with the incorporation of nonnative porphyrins into high-throughput screens that test both metal and amino
acid substitutions. Brustad and Arnold demonstrated that, in conjunction with in
silico analysis and a high-throughput testing of modified proteins, that enzymes
could be screened for enhanced activity for a native substrate 24. Although these
systems illustrate the value of porphyrin incorporation into a protein scaffold,
there are few instances where these proteins have been studied beyond the level
of product turnover assays.
The cytochrome P450 OleTJE presents an ideal scaffold for pursuing
reactivity studies of high-valent metal oxos. The ability to rapidly activate H2O2,
combined with possible contributions from the porphyrin electronics, allows for
the stable formation of a highly-accumulating ferryl-oxo π-cation intermediate
(Compound I) in the presence of native substrate 25. The significant kinetic
isotope effect of Compound I decay substantiates the need for quantum
tunneling for the hydrogen abstraction step 26-28. Following the hydrogen
abstraction step, hydrogen bonds originating from a water molecule stabilized by
the carboxylate of the fatty acid and His85 may be involved in stabilization of the
ferryl-hydroxo intermediate 29. The mechanism beyond this point is unclear.
However, the fatty acid decarboxylates and Compound II slowly decays over
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several hundred milliseconds to the starting ferric, low-spin state 30. The long
lifetime of these intermediates make P450oleTJE ideal for testing the
spectropscopic properties of this enzyme with porphyrins containing non-iron
metals.
As a proof of concept, we have adapted the ChuA coexpression for the
incorporation of Mn-PPIX in cytochrome P450oleTJE. Optical spectroscopic and
reactivity studies have been used to optimize conditions for high-level
incorporation of a non-native metal-containing porphyrin into the enzyme. The
reactivity of high-valent Mn-oxo complex with fatty acid substrates is reported.

3.2 MATERIALS AND METHODS
Synthesis of Manganese-Protoporphyrin IX
The synthesis of Mn-PPIX involved minor modifications of existing
protocols 31, 32. In a round bottom flask containing 20 mL pyridine, 100 mg of
protoporphyrin IX (Sigma Aldrich) was mixed with 725 mg manganese (II)
chloride and refluxed for either 6 hours or until the four characteristic Q-bands of
the free PPIX merged into two bands (Qx and Qy). The synthesis was followed
by UV-Vis with dissolution in pyridine. The round bottom flask was cooled to
room temperature and its contents poured into a separatory funnel. 80 mL of
200 mM HCl were added to the solution to solubilize any unbound metal and the
solution was vigorously mixed. 20 mL of chloroform were added to the solution
and mixed vigorously, with the organic phase (containing the porphyrin)
collected. This procedure was repeated three additional times on the aqueous
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layer until no color was observed in the organic layer. The porphyrin was
crystallized by evaporating the chloroform with a stream of nitrogen for 8 hours.
The contents of the container were collected and weighed for percent recovery
measurements, usually ranging from 98% - 104%. The purity was verified again
determined by dissolving the final product in DMSO and taking an optical
measurement and confirming that the metal was not labile during the extraction
process.
Expression of Manganese-PPIX OleT
pChuA, pLys, and p283-P450oleTJE Y110C vectors were co-transformed
into BL21 (Dε3) chemically competent cells. The function of the pLys gene is to
reduce the minimal amounts of T7 polymerase with the use of T7 lysozyme until
the culture is properly induced 33. A single colony from the transformation was
selected and used to inoculate an overnight culture consisting of LB media. 10
mL of the overnight culture were used to inoculate one liter cultures of modified
M9 minimal media recipe consisting of the following ingredients: 12.8 g sodium
phosphate, dibasic, 3 g sodium phosphate, monobasic, 0.5 g sodium chloride, 1
g ammonium chloride, 0.5% glycerol, 2 mM magnesium sulfate, 0.1 mM calcium
chloride, 0.1% casamino acids, 0.05 g kanamycin, 0.1 g ampicillin, and 0.02 g
chloramphenicol. The culture was the incubated at 37oC, 210 rpm until
OD 600 =0.5, when the temperature was lowered to 20oC and 400 µM magnesium
(II) chloride was added to each flask. The addition of the excess metal serves a
two-fold purpose in both discouraging demetalation of the porphyrin and inhibit
ferrocheletase from incorporating iron into endogenously produced porphyrin 34.
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After 20 minutes, 10 mg of Mn-PPIX dissolved in DMSO were added to each liter
of culture and incubated for 10 minutes, after which the plasmids were induced
with 50 µM IPTG and allowed to incubate for 30 hours. The cultures were spun
down at 6000 rpm for 15 minutes and stored at -80oC until lysed.
Purification of Manganese-PPIX protein derivatives
Cells were re-suspended in 200 mL buffer consisting of 50 mM sodium
phosphate, monobasic, pH=7.5, 300 mM sodium chloride, 10 mM imidazole
(Buffer A) and lysed via sonication for six 2 minute cycles separated by 5 minutes
of stirring on ice. The lysate was cleared by centrifugation for 40 minutes, 16000
rpm and the supernatant was decanted onto a 10 mL Ni-NTA column preequilibrated with Buffer A. The column was then washed with 30 column
volumes of Buffer A + 10 mM imidazole and eluted with Buffer A + 240 mM
imidazole. Ammonium sulfate was added to the elution at a final concentration of
25%, centrifuged, and decanted into a separate container. P450Olet was then
salt-cut with ammonium sulfate to 60% and centrifuged. The supernatant was
discarded and the pellet was resuspended with 100 mM potassium phosphate,
pH=7.5 and dialyzed twice in buffer.
The solution was loaded onto DEAE resin equilibrated with 50 mM
potassium phosphate, pH=7.5. The column was subsequently washed with
phosphate buffer + 50 mM sodium chloride. The protein was eluted using a
stepwise gradient of phosphate buffer supplemented with 100, 150, 200, 250,
300, 400, and 500 mM sodium chloride and the fractions containing porphyrin
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were pooled together. The protein was salt-cut and re-suspended to a final
concentration of 70 µM prior to dialysis and storage at -80oC.
Pyridine Hemochromagen Assay
The conditions for the porphyrin hemochromes are similar to published
methods 35. For both PPIX-Olet and Mn-Olet, 500 µL of a 5 µM protein solution
was diluted to 1 mL with a 40% pyridine/200 mM sodium hydroxide mixture and
mixed. A spectrum of this oxidized sample was taken prior to the addition of
solid sodium dithionite, when another spectrum was taken. Similar spectra were
taken for an unquantified amount of Fe-PPIX and Mn-PPIX for comparative
purposes and to account for contaminants during the preparation of the MnPPIX.
General Characterization of Mn-Olet
All measurements were made on an Agilent 8453 UV-Vis
Spectrophotometer using quartz cuvettes (Starna Cells, Inc.) with a path length
of 10 mm and a 4 mm slit width with or without an anaerobic screw-cap. The
concentration of enzyme was calculated using an assumed extinction coefficient
of 80 mM-1 cm-1. The manganic form of the protein was taken with 5 µM of aspurified enzyme in 200 mM potassium phosphate, pH=7.5. The bound form of
the spectrum was taken with treatment of 8 µM of as-purified enzyme with 48 µM
C20H fatty acid solubilized with 30% Triton-X/70% ethanol at room temperature
for 15 minutes followed by incubation on ice for 1 hour. The sample was spun
down at 4oC and the spectrum taken.
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The dissociation constant was determined by titration of eicosanoic acid to
5 µM of manganic enzyme and incubation overnight at 4oC. The samples were
centrifuged and measured. The increase of absorbance at 465 nm was plotted
against the concentration of fatty acid and fit in OriginPro 2017 using a quadratic
function (Morrison equation) reliable for the determination of tight dissociation
constants, where A max is the maximal absorbance change at ligand saturation, S
is the concentration of eicosanoic acid, E t is the concentration of enzyme, and K d
is the dissociation constant:
𝐴𝐴𝐴𝐴𝑏𝑏𝑠𝑠 = �

𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴
� (𝑆𝑆 + 𝐸𝐸𝐸𝐸 + 𝐾𝐾𝐾𝐾) − (((𝑆𝑆 + 𝐸𝐸𝐸𝐸 + 𝐾𝐾𝐾𝐾)2 − (4𝑆𝑆𝑆𝑆𝑆𝑆))0.5 )
2𝐸𝐸𝐸𝐸

The manganous form was obtained by first degassing 5 µM fatty acid
bound enzyme with 250 nM methyl viologen for 30 minutes. Two molar
equivalents of sodium dithionite solution were added to achieve a reduced
spectrum. The high-valent oxo complex was observed with the addition of
excess hydrogen peroxide to the reduced protein.
Stopped-flow kinetics of Mn-Olet
The measurement of the formation of the high-valent oxo intermediate
required the use of an SX20 Stopped-flow spectrophotometer (Applied
Photophysics) for accurate visualization and rate measurements. The
temperature of the experiment was set to 4oC and data were collected in
logarithmic mode for 60 seconds with 5000 time points with the PDA detector
and 5000 time points with the PMT detector. All data fittings and visualizations
utilized the Applied Photophysics Pro-Data SX software. 10 µM enzyme present
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in excess proteated or deuterated eicosanoic acid was loaded into Syringe A with
Syringe B containing one of the following oxidants: 5 mM hydrogen peroxide,
160 µM mCPBA, 3.2 mM sodium hypochlorite, or 5.2 mM peracetic acid. The
reaction was mainly followed at 420 nm representing the increase of the highvalent oxo intermediate and 376 nm representing the decrease of the Soret band
for the manganic form of the enzyme.
Rates were observed for the formation of the high-valent oxo intermediate
at 420 nm, which corresponds to a partial depletion of the manganic Soret band
at 376 nm, and fit using the following equation,
𝑛𝑛

𝐴𝐴𝑡𝑡,𝑜𝑜𝑜𝑜𝑜𝑜 = 𝐴𝐴∞ + � 𝑎𝑎𝑖𝑖 𝑒𝑒 −𝑡𝑡/𝑡𝑡𝑖𝑖
𝑖𝑖=1

where 𝐴𝐴𝑡𝑡,𝑜𝑜𝑜𝑜𝑜𝑜 is the observed absorbance, 𝑎𝑎𝑖𝑖 is the amplitude of phase i, t is time
in seconds, and 𝐴𝐴∞ is the final absorbance of the trace. Collected data were

fitted at 420 nm, the wavelength for the formation of the Mn-oxo intermediate.
The traces were fitted using a two-summed exponential representing two distinct
phases in the time trace, with the first phase showing the concerted decrease of
the manganic Soret at 376 nm and increase of the high-valent oxo species at 420
nm followed by a slow decay phase. This slow decay is composed of two
components: the decay of the high-valent oxo species to the manganic form and
the overall degradation of the Soret bands as the protein is hydrolyzed in the
presence of excess peracetic acid.
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A Hammett plot for the reactivity of the high-valent oxo species for phenol
derivatives involved hand-mixing 5 mM peracetic acid with 8 µM enzyme and
aging for at least 30 seconds prior to loading into Syringe A. Syringe B contained
2 mM of one of the following: phenol, 4-methoxyphenol, 3-chlorophenol, 1,3benzenediol, 1,4-benzenediol, or 4-cyanophenol. The rates were plotted as the
log of the rate for the formation of the high-valent oxo species for each derivative
divided by its rate of formation for phenol against the Hammett sigma constant
for each derivative. A linear fit was used to determine the ρ-value, which
indicates the nuleophilicity of the intermediate and the favorability of the reaction.
Analysis of turnover products
The protocol for turnover analysis has been used previously 30, 36. In
general, 2 mL of 5 µM enzyme supplemented with 500 µM of C20, C16, or C12
fatty acid were stirred at room temperature while a solution of 5 mM hydrogen
peroxide was titrated at a rate of 2 mL/hr for approximately one hour. Four drops
of concentrated HCl were subsequently added to quench the reaction and
protonate excess fatty acid and the solution was mixed for an additional 10
minutes. The products and excess fatty acid were extracted from the aqueous
phase with 4 mL chloroform, vortexed at maximum for 1 minute, and centrifuged
at 2200 rpm for 3 minutes. The organic layer was transferred to glass vials,
where the chloroform was evaporated on ice with a nitrogen stream. The
contents were derivatized with 200 µL BSTFA:TMCS (Sigma-Aldrich, 99:1) for 60
minutes at 60oC. Samples were stored at -20oC to prevent degradation of the
derivatized products.
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Turnover products were analyzed with a Hewlett-Packard 5890 Series II
Gas Chromatography (GC) instrument featuring a 30 m DB-5ms column with a
column head pressure ranging from 7 and 15 psi and fitted with a flame ion
detector. 7 µL of the derivatized sample were injected onto the GC and run on
two potential programs depending on the initial fatty acid chain length. For chain
lengths greater than C16, the following temperature gradient was established: 3
minutes at 170oC, 5oC/min to 260oC, 10oC/min to 320oC, 2 minutes at 320oC.
For chain lengths less than C16, the following temperature gradient was used: 3
minutes at 50oC, 5oC/min to 170oC, 10oC/min to 280oC, 3 minutes at 280oC. All
chromatograms were analyzed on HP ChemStation software.

3.3 RESULTS AND DISCUSSION
The synthesis of the Mn-PPIX was according to established protocols,
with nearly 100% incorporation of the manganese metal into PPIX. As the
oxidized form of the metal does not readily react with oxygen, the reaction did not
require anaerobic conditions. Care was taken during the extraction process not
to significantly lower the pH of the solution as this will result in demetalation of
the porphyrin 37. There are conflicting measurements concerning long-term
storage causing the demetalation of Mn-porphyrins in aqueous solutions. In
some cases, manganese porphyrins have been observed to demetalate in
aqueous solutions 38, 39. In other studies, no significant amount of free
manganese ions present in solution over an extended period of time 40, 41. To
alleviate these potential issues, the extracted porphyrin was crystallized and
stored at -20oC until further use. Furthermore, the required amount needed for
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growth was measured and solubilized in DMSO just prior to induction of E. coli
cells. Using these procedures, there has been no evidence indicating the
creation of free porphyrin in the final spectrum of the purified protein.
The presence of manganese in the purified enzyme was verified with the
hemochromagen assay, which removes the protein scaffold and replaces the
distal and proximal ligands of the metalloporphyrin with pyridine. The results
show that there is no iron present in the sample, concluding that the porphyrin
did not demetallate in solution and the intake of the required porphyrin outpaces
the native production of the iron porphyrin (Figure 3.2). This is also verified by
incubating a sample containing carbon monoxide with dithionite and not
observing a distinct peak at 450 nm, the symbolic location for an iron-loaded
P450 (Figure 3.3).
The spectrum of the protein as-purified contains a Soret peak at 376 nm, a
red-shift of around 20 nm compared to the Soret maximum for manganesereconstituted horseradish peroxidase (Mn-HRP) 42, and a blue-shift of around 10
nm compared to manganese-reconstituted P450 BM3 (CYP102A1, Mn-BM3) 43.
The Soret is reminiscent of manganese-reconstituted P450 CAM (CYP101), with
the positioning of the features nearly identical to those observed for Mn-OleT, but
lacks a pronounced shoulder at 420 nm 44. It is currently not known whether the
Soret differences among these P450s are due to positioning of the porphyrin or
subtle difference in the thiolate ligand (e.g. hydrogen bonding). There appears to
be minimal differences of the spectrum of Mn-Olet compared to what is observed
with manganic myoglobin (Mn-Mb) 45. There is also a shoulder emanating at 420
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nm that appears to be present, although in a diminished form, with Mn-Mb and
Mn-HRP. The absorbance intensity is reminiscent of manganese-substituted
P450 BM3, which portrays a more pronounced shoulder at wavelengths higher
than the Soret maximum. A sharp, manganese-specific band emanates from
465 nm. Its ratio of A 465/376 = 0.15 is more subdued compared to Mn-HRP and
Mn-Mb (~0.6-1.0), but not obliterated as is the case with P450s Mn-CYP101 and
Mn-BM3. Q bands are present at 560 nm and 590 nm with an additional feature
located at 515 nm. Mn-HRP shows Q bands located in a similar region. MnBM3 also contains identifiable Q-bands around 525 and 560 nm, similar to their
placement in Mn-Olet.
Alterations in the spectrum are noticeable with the addition of C20 fatty
acid (Figure 3.4). Unlike Fe-containing P450s, which can exhibit low- to highspin (HS) shifts upon substrate binding, manganic porphyrins are HS regardless
of ligand-binding due to occupancy of the σ* orbital at the d z 2 position, which is
usually unoccupied in the unbound ferric porphyrin 46, 47. As a result, the
mechanism of this change has yet to be elucidated for Mn-OleT but may signal
an environmental change at the thiolate-ligand. The titration of fatty acid to MnOleT causes neither shifting nor bleaching of the Soret. However, the Q bands
become more pronounced at 550 nm and 585 nm. Other spectra have not been
found to confirm the regularity of this behavior since the majority of proteins
studies are derivatives of Mb, which start in a ferrous, high-spin state to facilitate
binding of molecular oxygen 48. There is a 1.7-fold increase in the feature at 465
nm with the titratable addition of fatty acid as well as a 2 nm hypsochromic shift.
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Titration of the solvent (Triton-X/Ethanol) used to solubilize the eicosanoic acid
did not yield a spectral change.
The reduced spectrum for Mn-Olet shows a shift in the 465 nm feature to
432 nm along with an increased prominence (Figure 3.5). In addition, the Soret
shifts from 376 nm to 380 nm with a decrease in absorbance intensity to 75% of
the original, manganic peak. The Soret behavior is not known for Mn-CYP101;
however, the 465 nm feature also forms at around 430 nm with a strong,
prominent absorbance. The drastic increase of this feature upon reduction is
observed in synthetic manganese-porphyrins. Manganese(III)-mesotetrapyridinyl-porphyrin (Mn(III)TPyP), in the presence of hydrogen peroxide,
displays a bathochromic of the 465 nm feature and the decrease of the Soret 49.
The Soret shifts in this synthetic porphyrin as well, but to higher energy
wavelengths and are not observed with Mn-Olet. The Q bands also become
stronger while the 515 nm feature decreases, which is also observed in
Mn(III)TPyP.
The generation of a high-valent Mn-oxo species was attempted using
different oxidants, and led to differing results, summarized in Figure 3.6. There
was little to no noticeable oxo formation in the presence of hydrogen peroxide.
The addition of meta chloroperoxybenzoic acid (mCPBA) produced a stable oxo
complex, but did not accumulate in high yields. There was a great amount of
accumulation with sodium hypochlorite, with nearly half of the manganic form
converted within one second. However, the species quickly decayed to a new
species that most likely signaled the dissociation of the thiolate ligand from the
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porphyrin. The addition of peracetic acid yields similar quantities of oxo
intermediate which remains stable for minutes when using low concentrations of
oxidant. At higher concentrations (> 3 molar equivalents), the porphyrin
absorbance decays until the signal is completely bleached. The high
accumulation of the peracetic acid must be the oxidative species driving the
creation of the oxo intermediate.
The absorbance of the Soret band reduces in intensity and shifts to a
presumptive high-valent oxo species at 420 nm (Figure 3.7). The expected
peroxide shunt pathway would result in a porphyrin that is oxidized by 2 redox
equivalents relative to the starting state. In the case of reactions of Mn(III), this
would be anticipated to generate a reactive Mn(V) or a Mn(IV) porphyrin pi-cation
radical. The absorbance features of the latter would generate an absorbance
feature in the visible region at wavelengths > 600 nm. Such a species is not
evident from the rapid mixing studies shown here. Alternatively, it is also
possible that a highly-reactive Mn(V)=O species is transiently generated but
reduced rapidly by redox active amino acids from the protein framework (e.g. a
nearby tyrosine and tryptophan) to generate a less-reactive Mn(IV) species. An
example of this reaction is illustrated in Figure 3.8.
A scheme that summarizes the anticipated electronics of Mn(IV) and
Mn(V) species are shown in Figure 3.9. The formation of the high-valent oxo
intermediate is similar to those observed with Mn(IV)-BM3 and Mn(IV)-CYP101,
with an increase in absorbance at 420 nm corresponding to a decrease in the
manganic Soret at 376 nm. In order to study this intermediate, the manganic
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form of the enzyme was reacted against different oxidants, with the most stable
mechanism used for study. In addition to the changes at 376 nm and 420 nm,
peracetic acid bleaches the split Soret present at 465 nm and the manganic Qbands while the addition of mCPBA or hypochlorite produce minimal yields of the
high-valent species. The addition of sodium hypochlorite frees the porphyrin
from the protein scaffold quickly after forming the high-valent intermediate, as the
spectrum of the porphyrin aligns with free Mn-PPIX in aqueous solution after 30
seconds of incubation. Therefore, the peracetate was chosen for stopped-flow
analysis of the presumed Mn(IV) intermediate. Alternatively, creation of the highvalent oxo species has been utilized with the addition of hydrogen peroxide to the
manganous form of the enzyme and causing the formation of the peak at 420
nm, giving further credence that the high-valent oxo species produced is Mn(IV)
rather than Mn(V) (Figure 3.10).
Kinetic data shows the presence of either two or three phases during the
reaction of as-purified Mn-Olet with varying concentrations of peracetic acid, with
kinetic traces at 420 nm summarized in Figure 3.11. The reciprocal relaxation
times derived from multiple summed-exponential fitting are shown in Table 3.1.
Provided that the first phase results from the generation of the oxo intermediate,
the saturating behavior suggests a multi-step reaction in which an initial binding
step in followed by an irreversible step. Such a scheme would be consistent with
formation of the Mn(IV) species as a result of reduction from an exogenous
source such as a redox-active amino acid. However, the origin of this first phase
could also be the result of peracetate gaining quicker access to the active site in
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the portion of the sample that did not purify bound to palmitic acid, as is observed
in the iron wild-type enzyme 25. The second, slower growth phase is linearly
dependent on peroxide, and may reflect this binding step. The third phase,
present at higher concentrations of peracetic acid, is likely a slow decay phase
that results from decomposition of the porphyrin, resulting in bleaching.
The kinetics of oxo formation were also examined in the presence of a FA
substrate under saturating conditions and a fraction of the accumulation is
observed. Under normal circumstances, this small molecule contaminant can be
removed by treatment with a few molar equivalents of hydrogen peroxide
followed by treatment with BioBeads to remove the alkene product. However,
attempts at turnover with hydrogen peroxide with the Mn-substituted enzyme with
saturating eicosanoic acid shows no formation of C19-alkene product, as
determined by Gas Chromatography. So the use of it is unclear whether this
approach will be particularly suitable for the Mn-substituted enzyme.
There is little accumulation of the high-valent oxo intermediate in the
presence of eicosanoic acid, so the majority of this analysis involves enzyme that
has been untreated with fatty acid prior to treatment with peracetic acid but still
contains fatty acid contaminant from the purification process. In the presence of
low concentrations of peracetate, the enzyme undergoes a quick burst-phase
followed by a slow growth. Increasing the concentration of peracetate above a
certain threshold created a third phase representing a slow decay. The first
exponential for the formation of the 420 nm peak shows an initial rate of
formation for the high-valent oxo intermediate of less than 1 s-1 with a peracetic
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acid concentration at 125-fold excess to the enzyme. Increasing the peracetate
concentration above this threshold increases this initial rate to 5 s-1. The
composite spectrum extracted from SVD analysis (Figure 3.12) shows this phase
reaches completion within five seconds post-mixing with peracetate while slower
second phase completes the total accumulation of the oxo intermediate. The
comparative quickness of this RRT compared to the latter rates is likely due to
peracetate having ease of access to a portion of the sample that purifies nonfatty acid bound, as there likely is difficulty for the peracetate to enter the active
site of the enzyme when longer chain fatty acids are bound to the enzyme.
However, it is difficult to discern what percentage of the enzyme is bound with
fatty acid post-purification due to the lack of an optically observed spin-shift with
Mn-PPIX. Titration of Fe-Olet with eicosanoic acid does not shift the enzyme
fully high-spin, but rather accumulates between 88%-93% high-spin with the
remaining portion assumed to be in an inactive state. An explanation of the initial
burst phase may be given if the Mn-substituted enzyme behaves similarly to the
iron wild-type and the 7%-12% partitioned as “dead enzyme” is still able to react
with peracetate.
The second phase for the non-fatty acid bound sample shows a rate that
is one order of magnitude slower than the first phase. There is a consistency to
the rates, with oxo formation at less than 0.1 s-1 with 50-fold excess of peracetate
and goes no higher than 0.12 s-1 in the presence of 750-fold excess of oxidant.
In the presence of a 24,000-fold excess of peracetate, the rate of oxo formation
never reaches greater than 1 s-1, possibly due to difficulty for the oxidant
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navigating fatty acid contaminant to the manganese metal. The ratio of A 420/376
remains consistent after full accumulation of the oxo intermediate, indicating that
this is a stable, weak oxidant that achieves around 55% accumulation. This
contrasts with the formation of Compound I in the iron wild-type enzyme since it
is already in a state of decay to Compound II within the first millisecond on the
Stopped-flow. Due to its reactivity with the fatty acid substrate, the formation rate
of Compound II is around 70 s-1, an order of magnitude quicker than with MnOlet.
Rates were also measured for samples treated with eicosanoic acid
under saturating conditions to determine if peracetate can navigate past the
channel blockage created by the fatty acid contaminant. This data also fit to a
two-summed exponential with an initial burst-phase and a slow growth phase.
The initial phase for the fatty acid treated sample increases to 0.624 s-1,
compared to the rate of the non-fatty acid treated sample of 0.0802 s-1 (Figure
3.13). The second rate similarly increases for the fatty acid treated sample from
.0155 s-1 compared to the non-fatty acid treated sample at 0.0013 s-1. While
saturation of the enzyme with eicosanoic acid prior to treatment with peracetic
acid increases the rate of formation for the high-valent oxo intermediate, the total
accumulation is only about 30% compared to a paired reaction without the
addition of eicosanoic acid. The ability for the peracetic acid to access the active
site appears to be hindered due blockage by the fatty acid contaminant. The oxo
intermediate appears to be stable with no apparent decay of the high-valent
intermediate. In fact, the second RRT for the fatty acid bound time trace
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continues to increase slightly after 60 seconds whereas the non-fatty acid treated
enzyme has already begun to decay. In is currently unclear why the rates are
quicker for the fatty acid bound enzyme since stearic hindrance should decrease
the rate for the formation of the intermediate.
Enzyme with no additional fatty acid bound shows an increase in the
bleaching of the Soret band at peracetate concentrations greater than 375-fold
excess to the enzyme. The effect of porphyrin degradation is slow at lower
concentrations, leading to a decay of less than 0.002 s-1 when under a 6000-fold
excess of peracetate. At 24,000-fold excess of oxidant, the decay rate climbs to
0.008 s-1. The reason for the decay is still unknown, but it is possible that the
peracetate is hydrolyzing the porphyrin after the addition of one equivalent of
oxidant and renders the enzyme catalytically inert. Since Fe-Olet turns over
substrate, there is less concern for inactivation of the enzyme since excess
peroxide in solution may be continuously converted to water molecules.
The substitution of iron with manganese leads to a decrease in reactivity
for Olet. The stability of this intermediate is persistent regardless of fatty acid
presence in the active site of the enzyme, indicating that the Mn(IV) oxidant is not
strong enough to abstract a hydrogen atom from a carbon atom that contains a
bond dissociation energy of 98 kcal/mol. This also confirms that the formation of
the oxo peak is not due to Compound II formation, which was observed by Grant
in Fe-Olet, since there is no apparent decay of the intermediate to a low-spin
state. Proteins that have been substituted with Mn-PPIX show the ability to
epoxidize styrene and to hydroxylate weak carbon bonds. However, there is no
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evidence for the conversion of styrene to styrene oxide with Mn-Olet and also no
data demonstrating reactivity with C-H with lower BDEs, such as phenols and
phenol derivatives.
However, the enzyme is capable of abstracting a hydrogen atom from
phenol and phenol derivatives. This was determined through the use of a
Hammett plot (Figure 3.14), utilizing phenolic derivatives as substrate. The
affinity of the enzyme for hydrogen-abstraction from one of these substrates is
dependent on the electron donating character of the substrate and the acidity of
the high-valent oxo species within the enzyme. The variation of the rate of
formation of the oxo species with electron-donating groups suggests rapid
hydrogen abstraction, which follows the pattern of the iron-bound porphyrin in the
wild-type enzyme and its affinity for nucleophilic attack on fatty acid substrates.
The decrease of oxo decay with electron-withdrawing groups suggests that the
porphyrin is still tuned to hydrogen abstraction and does not allow for
electrophilic attack. The slope of the variation in the reaction rate against the
Hammett (σ) constant, which indicates the effects of the molecule’s polarity,
gives a ρ value of 1.2. The weakness of the slope implies a weak activation of
the substrate and its positive value suggests the decay of the high-valent oxo
intermediate is mediated by a hydrogen abstraction step and not the formation of
a cationic species. The shift in the Soret from 420 nm to 376 nm in the presence
of the strongly activating constitutents further implies that the active intermediate
is a Mn(IV)-oxo, as the Mn(V)-oxo intermediate would be sufficiently acidic to
perform a hydrogen abstraction from weakly-deactivated phenolic derivatives.
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3.4 CONCLUSION
Mn-Olet is a useful tool for determining the feasibility of incorporating noniron PPIX to an overexpressed P450 in liter quantities with the use of ChuA. The
reactivity of the enzyme to multiple forms of oxidative species show that the
weaker acidity of the manganese needs a stronger oxidant for activation, with
peracetate having more success compared to the hydrogen peroxide cofactor
used by Fe-Olet. The protein itself, with its ability to achieve a high valent oxo
intermediate, is useful for testing the ability of a variety of small molecules to
enter the active site of the protein. Based on treatment with different oxidants
containing different physical characteristics, Eicosanoic acid typically blocks
bulkier small molecules from entering the pocket. When fatty acid substrate does
enter the active site, the lack of reactivity and the stability of the high-valent oxo
intermediate demonstrate difficulty in cleaving C-H bonds with high BDEs.
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Figures and Tables

Figure 3.1: Diagram of non-native porphyrin incorporation into the cell
with ChuA. “M” is any metal capable of seating correctly in Protoporphyrin IX.
ChuA is the importer protein, PBP is the periplasmic binding protein, and ABC is
the ATP-dependent binding cassette.
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Figure 3.2: Pyridine hemochromagen assay for Mn-Olet and Fe-Olet.
Assay conducted with 10 µM of either Fe-Olet or Mn-Olet. For both comparison
and validation that the enzyme is iron-free, 8 µM Fe-Olet was used as a control.
The lack of an overlap at the α-band for the Mn-Olet confirms undetectable
amounts of iron in the protein (< 95%).
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Figure 3.3: CO difference spectrum for Mn-Olet. Assay conducted with 4
µM reduced Mn-Olet. The black trace is anaerobic Mn(III)-Olet incubated with
carbon monoxide. The red trace is upon the addition of excess sodium dithionite
solution. There is no obvious peak formed at 450 nm, suggesting the lack of FeOlet present in the solution.
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Figure 3.4: Determination of K D using the optical changes at 463 nm for
Mn-Olet. The dissociation constant was determined with 4 µM Mn-Olet and
eicosanoic (C20:0) fatty acid in triplicate. The K D is similar to one obtained for
Fe-Olet, which is 110 nM (Chapter 4).
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Figure 3.5: Optical characterization of Mn-Olet. 4 µM Mn(III)-Olet (in
black) is reduced with excess sodium dithionite in an anaerobic environment to
form Mn(II)-Olet (in red).
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Figure 3.6: High-valent oxo species formed by Mn-Olet utilizing different
oxidants. For all traces, 10 µM of Mn(III)-Olet were reacted against differing
oxidants, whose concentrations were dependent on protein stability. 5 mM
hydrogen peroxide reacts, but does not achieve high accumulation. 0.16 mM
mCPBA yields a small, but stable accumulation of the intermediate species. 3.2
mM sodium hypochlorite reacts to briefly form high accumulation of intermediate,
but subsequently decays to a form of the enzyme where the thiolate ligand is
removed from the Mn-PPIX. 5.2 mM peracetic acid forms and maintains high a
high accumulation of high-valent oxo complex with minor bleaching dependent
on the peracetate concentration. The lack of formation for hydrogen peroxide
indicates that the peracetate is the active reagent in this reaction.
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Figure 3.7: Stopped-flow spectra of high-valent oxo formation in Mn-Olet.
This details the first 39 seconds of the peracetate panel in Figure 3.6 at 4oC.
Final concentrations after mixing are 8 µM manganese OleT and 1.5 mM
peracetic acid.

Figure 3.8: Proposed reduction pathway from the Mn(V)=O to Mn(IV)=O.
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Figure 3.9: Molecular orbitals for proposed oxidation state transitions for
Mn-Olet upon addition of oxidants. A) The pathway for the formation of the
Mn(IV) oxo species beginning with the manganous form of the enzyme and the
addition of hydrogen peroxide. B) The pathway for the formation of the Mn(V)
oxo species with the addition of peracetate to the manganic form of the enzyme.
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Figure 3.10: Optical spectra of Mn(IV)=O formation with reduced Mn-Olet
and hydrogen peroxide. 4 µM Mn-Olet (as-purified) is reduced with 1.5 molar
equivalents of sodium dithionite in an anaerobic environment. After full
reduction, 50 µM hydrogen peroxide was added to the cuvette and mixed.
Spectra were taken until the enzyme oxidized back to its manganic state. The
peak at 420 nm is likely a high-valent oxo intermediate forming prior to its decay
to an Mn(III) state.
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Figure 3.11: Time traces of differing concentrations of peracetate mixed
with Mn-Olet. Measurements were taken by Stopped-flow at 4oC with 8 µM
Mn(III)-Olet rapidly mixed with peracetate and observed for the formation of the
oxo intermediate at 420 nm. The decay phase constitutes the bleaching of the
porphyrin absorbance, and not a decay to the Mn(III) form of the enzyme.
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Table 3.1: Rates of Mn(IV)-oxo formation reacted with differing concentrations of
peracetic acid.

A quick burst phase is present in each trace, represented by the first rate.
This is either followed by or coincides with the slow accumulation of the oxo
species to its maximum concentration, represented by the second rate. The third
rate exerts itself at high concentrations of peracetic acid and is representative of
the bleaching of the porphyrin absorbance, not the regression of the high-valent
oxo intermediate back to the manganic form of the enzyme.
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Figure 3.12: SVD spectra of the proposed pure Mn(IV)=O species with
the speciation plot. These spectra were extracted from the two growth phases
occurring during the first 30 seconds of the reaction of 8 µM Mn-Olet with 1.5 mM
peracetate. The black trace is the manganic form of the enzyme, the red trace is
the fast growth rate of the reaction, and the blue trace is the slow growth rate of
the reaction. The inset shows the concentration of each state as a function of
time.
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Figure 3.13: Stopped-flow spectra of Mn(IV)=O formation of Mn-Olet with
(right) and without (left) eicosanoic acid. 2 µM Mn-Olet treated with 70 µM
peracetic acid post-mix on the Stopped-flow at 4oC. Treatment with C20 fatty
acid inhibits entry of the peracetate into the active site of the enzyme, allowing for
a smaller accumulation of the high-valent oxo intermediate. The first oxo
formation rate without additional fatty acid is 0.0802 s-1 and a second rate of
0.0013 s-1, while the first rate with additional fatty acid is 0.624 s-1 and a second
rate 0.0155 s-1
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Figure 3.14: Hammett plot for Mn-Olet with phenol derivatives. The plot
was prepared from measuring the rate of oxo formation at 420 nm for each
derivative followed by normalization with phenol. The log of this normalized factor
is then plotted against the known Hammett coefficient (sigma) for each
derivative. The formation rates were measured by stopped-flow at 4oC by rapidly
mixing 5 mM peracetic acid with 8 µM Mn-Olet incubated with 1 mM of phenolic
derivative.
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CHAPTER 4
RE-TUNING THE REACTIVITY OF THE FERRYL-OXO INTERMEDIATES IN
P450OLET THROUGH SUBSTITUTION WITH IRON-MESOPORPHYRIN IX
4.1 INTRODUCTION
Alteration of the redox potential of an enzyme is a technique often used to
study its change in catalytic behavior and develop a catalyst that promotes the
production of a highly desired product that is not normally produced by the native
enzyme. Traditional techniques involve one of two methods. The first method
relies on the identification and mutagenesis of residues providing the first or
second shell interaction with the catalytic metal while the second method
requires the denaturation and removal of the native metal porphyrin and
incorporation of the desired one. However, these studies rarely involve thiolateligated P450s that perform decarboxylase-specific chemistries. Both of these
methods have potential difficulties, since mutagenesis requires alteration of the
environment surrounding the sole endogenous ligand to the metal and the
incorporation of a non-native porphyrin finishes with low yields due to the harshly
acidic conditions involved with denaturation and removal of the thiolate-ligated
porphyrin.
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More modern methods that have been successfully used for the
incorporation of non-native porphyrins through the use of knockout mutations
involved in porphyrin biosynthesis in the RP523 cell line 1-3. Unfortunately, these
require stringent growth conditions involving minimal media in an anaerobic
environment, as to disfavor the formation of radical oxygen species 4, 5. A softer
approach is the use of the bacterial heme importer ChuA for the acceptance of a
non-native porphyrin 6. Previously, it had been used to transport Mn, Fe, Co, and
Zn PPIX cofactors into E. coli for incorporation into P450 BM3 (CYP102A1) with
full incorporation of the added porphyrin 7. The use of this system with hemin
has also been reported to result in higher protein expression levels compared to
the reliance on native porphyrin synthesis in E. coli 8.
Myoglobin was among the first porphyrin-based proteins to be studied in
terms of studying the alteration of the redox potential. Mutations of the second
coordination sphere have been successfully incorporated into the protein
scaffold. Mutagenesis of the S92 residue involved in the second coordination
sphere for the proximal ligand of the F33Y mutant of myoglobin increases the
potential by 28 mV 9. Two distinctive changes to the porphyrin itself may also be
used, with the addition/reduction of carbons in the porphyrin and the alteration of
the porphyrin’s prosthetic groups. Alteration from vinyl groups to those with
electron withdrawing character, such as formyl groups, will decrease the affinity
of oxygen towards myoglobin due to the loss of π-electrons 10. Alteration of the
ring itself through the addition of more carbons without breaking aromaticity, as
with hemiporphycene, will increase the potential and as well as the affinity for
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oxygen and oxygen-like substrates 11, 12. Alteration this sort will allow myoglobin
to activate O 2 and perform hydroxylation chemistries and epoxidation on weak
carbon bonds.
Similar experiments involving the alteration of the reduction potentials in
cytochromes have also led to similar results. Mutation of the histidine ligand to a
methionine in the electron carrier cytochrome c3 increases the redox potential by
up to 200 mV 13, a trend comparable to same mutation in cytochrome c
increasing the potential by 230 mV 14. The shortening of the Fe-S bond length
decreases the potential of the protein, while its elongation provides an increase
in the potential 15. Bovine cytochrome b5, which functions as an electron carrier
to membrane-bound oxygenase enzymes, decreases the potential of the enzyme
by 83 mV when replaced with 2,4 dimethyldeuteroporphyrin 16. Model systems
mimicking myoglobin and cytochrome active sites have been used to calculate
equivalent redox potentials of various iron-porphyrins. Fe-PPIX has a redox
potential of -115 mV and Fe-Mesoporphyrin IX (Fe-MPIX) has a redox potential
of -158 mV, due to the lack of donating character through the transformation of
the 2,4 vinyl groups to alkyl groups 15.
Experiments involving the incorporation of non-native porphyrins into
enzymes with thiolate ligands have been performed to study the effect of
substrate interaction with an enzyme as a function of redox potential. Nitric
Oxide Synthase (NOS) demonstrates a decrease in the redox potential by
around 50 mV and an increased rate of peroxide activation when PPIX is
substituted with MPIX 17. Furthermore, Woodward attributed this to the
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concentration of the electrons within the porphyrin ring, leading to a “push” effect
to dissociate the distal oxygen of the bound H 2 O 2 and the subsequent
stabilization of the Compound I intermediate and a decrease in the rate of
product formation.
Porphyrin biosynthetic pathways within the cell are specific for the type of
metal that is to be incorporated into a given porphyrin. However,
misincorporation of the metal in vivo do occur and may also contribute to an
improperly installed porphyrin. There are occurrences when this effect has a
negative impact on the survivability of the cell, as is the case with an noncatalytically active metal such as zinc or copper is incorporated into PPIX 18.
Incorporation of these unreactive porphyrins will significantly reduce the oxygen
carrier’s, such as hemoglobin and myoglobin, activity or render them inert 19.
However, this also provides a useful mechanism to counteract excess metals
within the cytosol by incorporating them in an inert form 20. However, not all
porphyrins may be utilized as a replacement for hemin. Incubation of
apocytochrome c with iron-deuteroporphyrin (DPIX) does not yield a holoprotein,
but the apoprotein does reconstitute into its holo form after incubation with FePPIX 21.
P450olet performs decarboxylation upon its substrate 22 rather than the
hydroxyl radical rebound mechanism prevalent among P450 monooxygenases 2325

. The acid-alcohol pair present in CYP101A1 26 is replaced with an arginine-

proline pair which forms a salt bridge to the carboxylate of the fatty acid 27 and,
as observed on the C20H-bound crystal structure, inhibits the tail of the fatty acid
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from accessing a cavity present between the carboxylate residues of the
porphyrin (PDB ID: 4L40). Hydrogen peroxide binds to the ferric heme by taking
advantage of the “peroxide-shunt” mechanism usually present as a release
mechanism in canonical P450 oxygen activation 28. This allows two electron
equivalents to be incorporated by the oxygen species in lieu of two rounds of one
electron transfers with a ferredoxin. This makes the enzyme ideal for study in
vitro since all accumulated spectra carry no interference from iron-sulfur or flavin
contaminant signals. The binding of hydrogen peroxide is followed by the
removal of the proximal proton to give a ferric-hydroperoxo intermediate,
although the specifics of this portion of the mechanism is presumably not
elucidated with respect to P450olet due to its high reactivity 29.
The proton rebounds to the distal oxygen of the peroxide to form water
and subsequently pushed off, forming a ferryl-oxo π-cation intermediate known
as Compound I (Cpd. I), which is the first biologically observed species obtained
through its native mechanism 30. The life-span of this intermediate is notable
since it is rarely observed in the presence of the enzyme’s native substrate,
usually being isolated from a reaction between low-spin, ferric enzyme and an
activated peroxo-species such as mCPBA or peracetic acid 31. The rate of Cpd. I
decay is consistent with differing chain lengths, as it is always observed
abstracting a hydrogen atom from the β-position of the fatty acid. Although the
decay rate is similar, the accumulation of intermediate decreases with decreasing
fatty acid chain lengths-probably due to a decreased quantity of starting high-spin
enzyme. As Cpd. I decays, the ferryl-hydroxo intermediate known as Compound
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II (Cpd. II) forms. The lifetime of Cpd. II was verified through the use of the
radical clock norcarane 30, which confirm its stabilization in the range of
milliseconds, rather than on the level of picoseconds as is the case for canonical
P450 hydroxylases 32. QM/MM studies link the stability of Cpd. II to hydrogen
bonding networks that raise the activation barrier gating the rebound of the
hydroxyl radical back to the substrate, but it does allow for the extraction of a
second electron from the substrate 33. The exact nature of this stability still
unknown, as there are no studies confirming the method of decay of Cpd. II and
no structures firmly dictating the presence of stabilizing forces.
The mechanistic steps involved with the decay of Cpd. II back to the ferric,
low-spin form are still debated with two different mechanisms proposed. The
missing step involving rebound of the hydroxyl radical implies that a second
electron must be removed from the substrate in order to maintain a stoichiometric
number of electrons for the formation of an alkene and carbon dioxide. However,
the origin of this second electron is unknown, as it may be located on the oxygen
of the carboxylate, as proposed by Belcher 27 and verified on other alkeneproducing P450s 34, 35. This mechanism relies on a radical rearrangement
involving heterolytic cleavage between the carboxylate carbon and Cα, with one
electron to the carboxylate to form carbon dioxide and the other to joining with
the radical on Cβ to form a Cα=Cβ bond. The alternative mechanism involves
extraction of the second electron from the β-carbon radical, leaving a cation
intermediate 36. The electron pair on the carboxylate anion would form a π-bond
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with the carbon and homolytically cleave the bond between the carboxylate
carbon and the Cα, forming a Cα=Cβ bond.
Upon metabolism of C10-C16 fatty acids by P450olet, the formation of
hydroxylated fatty acids as minor products becomes apparent 30. The exact
reason for this is unknown, but it is likely that residues holding the ω-carbon in
place no longer have an effect, leading to more mobility for the fatty acid within
the enzyme’s active site. Although the amount of hydroxylated product increases
as fatty acid chain length decreases, the ratio of products remains constant in the
order of decreasing accumulation: alkene, β-OH, γ-OH, and α-OH fatty acid 37.
This suggests limits to the freedom for these shorter fatty acids within the active
site due to the presence of other residues responsible for stabilizing the fatty acid
that hydroxylation beyond Cγ.
Other peroxidase enzymes related to P450olet are known to metabolize
fatty acid substrates, notably the hydroxylation reaction of P450 BSβ 38, 39 and
P450SPα 40 and the decarboxylation chemistry of P450staph (not published).
However, no studies have been performed to test the effect altering the redox
potential will have on the product distribution for these enzymes. Ideally, the
enzyme would alter its current product count leading to a higher distribution of
alkene production for use as drop-in biofuels or the creation of new functional
groups easily for use in polymer chemistry, such as epoxides, would be essential
for the manufacture of polymers 41. The change in the potential observed
through modification of the porphyrin is driven by the change in electron density
of the ring and allows the formation of products that may be utilized in fields other
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than biofuels. Changing the metal from iron to manganese in PPIX raises the
redox potential, as mentioned in Chapter 3, leading to creation of epoxides with
certain molecules, such as the conversion of styrene to styrene oxide. On the
other hand, the reduction of the 2,4 vinyl groups in PPIX -creating MPIX- leads to
a decrease of the potential and provides a baseline in P450olet for products
catalyzed by a porphyrin with stronger affinity for oxygen adducts. Although this
may not be noticeable with fatty acids greater than C18 due to their inherent
stability within the pocket, the variation in products would be indicative of whether
it is more prudent to decrease or increase the potential of the porphyrin to alter
the current balance of hydroxylated product. In addition, the ability to discern
information concerning the intermediate steps of the reaction would also be
useful, especially given how the portion of the mechanism extending from Cpd II
decay to Ferric, low-spin has not been elucidated.
The redox potential of native P450olet is unusually positive, lying around 100 mV in both the Ferric, low-spin and Ferric, high-spin states 27. This is
peculiar since the low-spin redox potential for canonical P450s is below -300 mV,
as with CYP101A1 42 and P450cin (CYP176A1) 43, and prevents the transfer of
the first electron by their associated ferredoxin rather than position itself where a
redox partner is able to transfer electrons to the enzyme 44. Of interest are the
effects of altering the potential of the enzyme through non-native porphyrins and
two porphyrins were chosen. Fe-Mesoporphyrin IX (Fe-MPIX) lowers the
potential by about 50 mV and into the range of the redox potential for ferric, highspin CYP101A1 (Figure 4.1). 2,4-diformyldeuteroporphyrin IX (Fe-dfDPIX) raises
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the potential by about 70 mV, far outside the redox potential of known P450s.
Unfortunately, dfDPIX could not be incorporated due to hydrophobic residues
surrounding the 4-position of the porphyrin and stearically hinders polar groups
from seating correctly, as determined by the crystal structure referenced earlier.
This led to attempts at incorporation of stronger electron withdrawing group being
unsuccessful, leading to a single alteration of the redox potential for the purposes
of this study.

4.2 MATERIALS AND METHODS
Expression of MP Olet
The plasmid containing the P450olet Y110C mutant 45, cloned into a
pET283 vector with a T7 promoter and C-terminal 6x polyhistidine tag, was cotransformed with the vector pChuA (purchased from Addgene [plasmid #42539],
deposited by Alan Jasanoff) containing the gene for the expression of the
porphyrin importer ChuA into chemically-competent BL21 (Dε3) cells previously
transformed with the pLysS plasmid which reduces cellular background signal. A
single colony was transferred to an overnight culture and incubated for 12-16
hours. From this starter culture, 10 mL of inoculant were added to each liter of
M9 minimal media, which consists of the following: 12.8 g sodium phosphate,
dibasic, 3 g sodium phosphate, monobasic, 0.5 g sodium chloride, 1 g
ammonium chloride, 0.5% glycerol, 2 mM magnesium sulfate, 0.1 mM calcium
chloride, 0.1% casamino acids, 0.05 g kanamycin, 0.1 g ampicillin, and 0.02 g
chloramphenicol. The culture grew at 37oC, 210 rpm until it reached an
OD 600 =0.5. Upon reaching this OD, the temperature was dropped to 20oC and
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incubated for an additional 20 minutes, when 10 mg of Fe-MPIX (dissolved in
DMSO) were added to each flask. The culture incubated for an additional 10
minutes prior to induction with 50 µM IPTG and grown for 30 hours followed by
centrifugation for 15 minutes at 16000 rpm and freezing the pellet at -80oC.
Purification of MPolet
The pellet was resuspended in 50 mM potassium phosphate, dibasic,
pH=7.5, 300 mM sodium chloride, 10 mM imidazole (Buffer A) and sonicated at 2
minute cycles seven times with 5 minute breaks between cycles where the
solution was stirred on ice. The lysate was cleared by centrifuging at 16000 rpm
for 45 minutes and the supernatant was loaded onto a 25 mL Ni-NTA column that
had been pre-equilibrated with Buffer A. The column was subsequently washed
with Buffer A + 10 mM imidazole and the protein eluted with Buffer A + 240 mM
imidazole. The eluent was diluted with one equivalent of 55% ammonium sulfate
solution in 100 mM potassium phosphate, dibasic and cleared by centrifuging at
4400 rpm for 10 minutes to remove unwanted precipitant. The supernatant was
loaded onto a butylsepharose column pre-equilibrated with 30% ammonium
sulfate and washed with the same buffer. The protein was eluted with a gradient
from 30%-0% ammonium sulfate for 200 mL and 5 mL fractions collected. The
fractions containing A 412/280 > 0.9 were pooled and precipitated with by adjusting
the concentration to 60% ammonium sulfate and centrifuged as above. The
precipitated protein was resuspended in a minimal volume of 200 mM potassium
phosphate, dibasic, pH=7.5 and dialyzed twice in 2 L of buffer. A 12% SDS-
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PAGE gel confirmed the purity of the enzymes prior to their experimentation
(Figure 4.2). The purified protein was flash-frozen and stored at -80oC.
UV-Vis
All UV-Vis spectra were taken with an Agilent 8453 UV-Vis
Spectrophotometer and analyzed on their proprietary data collection software
and with the Origin software package. The spin-state spectra were determined
by taking 5 µM protein and adding one equivalent of hydrogen peroxide, shifting
any high-spin protein to a low-spin form. Four molar equivalents of eicosanoic
acid were subsequently added and incubated for one hour on ice, centrifuged at
14000 rpm for 10 minutes, and the spectrum taken for the fully high-spin
spectrum. Two molar equivalents of hydrogen peroxide were mixed with the fully
high-spin protein to ensure that it was still fully active. The CO spectrum was
taken by degassing 5 µM protein in an anaerobic cuvette in the presence of 0.1
molar equivalents of methyl viologen. CO was bubbled into the cuvette for 5
minutes and the initial spectrum was taken. 3-6 molar equivalents of degassed
sodium dithionite solution were added to the cuvette, mixed, and the spectrum
immediately taken.
The dissociation constant (K D ) was measured in triplicate by taking
aliquots of 4 µM protein and adding 1 molar equivalent of hydrogen peroxide to
each tube, ensuring the spectrum is in a fully low-spin state prior to the start of
the titration. Eicosanoic acid (dissolved in 30% Triton-X/70% ethanol) was added
in 0.5 µM increments. The solutions incubated at 4oC overnight and centrifuged
for 5 minutes at 14000 rpm. Spectra were taken for all tubes, averaged, and the
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K D was calculated with the Morrison equation, a derivative of the MichaelisMenten equation for use on data that contains a dissociation constants tighter
than several micromolar.
Pyridine Hemochromagen assay
To determine the percentage of MPolet to PPolet, the pyridine
hemochromagen assay was used to detect the separation of band distinct for
both MPIX and PPIX. This protocol is a modification of a published protocol by
Barr 46. Briefly, one equivalent of a 40% pyridine/200 mM sodium hydroxide
solution was mixed with 6 µM MPolet and an oxidized spectrum taken on the UVVis. To obtain the reduced species, several grains of sodium dithionite were
mixed into the sample. This was repeated for PPIX as an additional reference
and also to discern differences between Fe-PPIX and PPolet. Impurities were
visually determined based on the absorbance of the α-band in the Q-region of the
spectra.
Stopped-flow measurements
The Stopped-flow observes the presence of enzymatic intermediates and
calculates the rates for any observable intermediates. All data were collected on
an Applied Photophysics Stopped-flow instrument using either a photodiode
array for full spectral collection or a photomultiplier tube for a single, high
resolution wavelength. Specific wavelengths observed were at 357 nm
(Compound I Soret), 410 nm (ferric, low-spin), 430 nm (Compound II), and 680
nm (Compound I π-cation radical). Unless otherwise stated, spectra were
collected under aerobic conditions at 4oC. All data were analyzed with the Pro-
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Data SX software program from Applied Photophysics and the Origin software
package.
To determine the rate of decay for Compound I, rate of formation for
Compound II, and the decay of Compound II, Syringe A was loaded with 10 µM
MP Olet incubated with a 4 molar excess of proteated or deuterated fatty acid
(C20, C16, or C12) and spun down for 10 minutes at 4400 rpm. Syringe B was
loaded with 10 mM hydrogen peroxide. Data were collected with one second,
logarithmic shots.
In order to determine the rate for peroxide association and dissociation
constants, 10 µM enzyme was treated with deuterated or proteated eicosanoic
acid as above and loaded into Syringe A. Syringe B contained hydrogen
peroxide ranging from 80 µM to 10 mM. The data was plotted as a function of k
vs peroxide concentration, with the y-intercept indicating the K D of peroxide and
the slope identifying the peroxide association with the enzyme.
An Arrhenius dependence plot was developed with a single-mix
experiment involving 8 µM MP Olet with deuterated eicosanoic acid prepared as
above and loaded into Syringe A. Syringe B was loaded with 10 mM hydrogen
peroxide. PMT data at the 430 nm wavelength, associated with the decay of
Compound I to Compound II and the decay of Compound II to low-spin, were
collected at three second intervals at a temperature range from 2oC to 23oC. The
rates were plotted as a function of ln(k) vs 1/T in Kelvin. The activation energy
was determined with the Arrhenius equation k=Ae^-(E a /RT), where k is the rate
of the decay from either Cpd. I to Cpd. II or Cpd. II to low-spin, A is a multi-
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variable parameter that contains distance to the substrate, E a is the activation
energy necessary to proceed to the next intermediate, R is the ideal gas constant
in kcal/mol, and T is the temperature in Kelvin.
Determination of turnover products
Turnover products were measured with a Hewlitt-Packard 5890 Series II
Gas Chromatography (GC) instrument featuring a 30 m DB-5ms column with a
column head pressure ranging between 7 and 15 psi and fitted with a flame ion
detector. For chain lengths greater than C16, the protocol is as follows: 3
minutes at 170oC, 5oC/min to 260oC, 10oC/min to 320oC, 2 minutes at 320oC.
For chain lengths less than C16, the protocol is as follows: 3 minutes at 50oC,
5oC/min to 170oC, 10oC/min to 280oC, 3 minutes at 280oC. The turnover
experiment involved 2 mL of 5 µM untreated protein + 500 µM of proteated fatty
acid (C20, C16, C14, and C12) in a flat-bottom glass vial. While stirring at room
temperature, a 5 mM solution of hydrogen peroxide was slowly titrated using a
multichannel pipettor at a rate of 2 mL/hr. After one hour, the titration was
stopped and the solution stirred for an additional 10 minutes. Four drops of 12 M
HCl were mixed for 5 minutes in each vial to aggregate the protein and protonate
the fatty acid.
The fatty acid was extracted using an equivalent volume of chloroform,
vortexed for 1 minute, and spun down for 3 minutes at 2200 rpm. The organic
layer was collected, transferred to a separate vial, and evaporated on ice under
nitrogen gas. The extracted material was derivatized with 200 µL BSTFA:TCMS
(Sigma-Aldrich) at a 99:1 ratio and incubated at 60oC for 1 hour. 7 µL of the
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derivatized contents were injected onto the GC with the program dependent on
the fatty acid chain length. Samples were stored at -20oC until shot to prevent
degradation of the derivatized products. The data for the chromatographs were
collected and peaks integrated on proprietary software from Hewlitt-Packard.

4.3 RESULTS
Characterization by UV-Vis
Post-purification, all peaks for MPolet associated with π-π* transitions are
hypsochromically shifted by 10 nm, leading to a Soret band at 408 nm, high-spin
band at 382nm, and α/β Q-bands at 565 nm and 530 nm, respectively. In
addition, there is a 10 nm shift for the Soret and Q-bands for the ferric, low-spin,
ferrous, and ferrous-CO complex in MPolet (Figure 4.3) when compared to
PPolet (Figure 4.4). This is similar to the spectral shift with MPIX incorporation
into horseradish peroxidase, which also observes a hypsochromic shift in these
peaks 47. The formation of the ferrous spectrum is similar to PPolet as well,
again with peak maxima blue-shifted by 10 nm to 402 nm. There is difficulty with
the shift from the ferric state to the ferrous state, with 3 molar equivalents of
sodium dithionite to successfully reduce the sample. This may be due to an
equilibration issue among the electron exchange that is not present with PPolet,
but common among NADPH and surrounding redox partners 48 or the lengthy
equilibration times for P450 BM3 redox potentiometry 49. The formation of the
carbon monoxide complex shows a uniform peak centered at 442 nm with no
indication of accumulation at 450 nm, which is the wavelength of the CO complex
with PPolet. The Q-bands merge to form a single band, which indicates an iron-
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thiolate ligand present in the sample. This intermediate is short lived as the
sample quickly decays from 442 nm to 410 nm, which corresponds to a 10 nm
difference observed by PPolet for a severed iron-thiolate bond and catalytically
inert enzyme 50-52.
The quantity of high-spin present post-purification is about 40%, which is
lower than the 50% for PPolet. The co-purification of substrate is not specific to
P450 peroxidases 53, but the low K D of long chain fatty acid provides an estimate
concerning the molecule in the active site. Although the enzyme does not purify
in an entirely high-spin state, two days of purification in continuously fresh buffer
undoubtedly rids a portion of the fatty acid from the enzyme preparation. Upon
the addition of excess eicosanoic acid, the spin-state shifts to about 80% highspin, which is around 10%-15% less than PPolet. However, the dissociation
constant for the MPolet/C20 pair is similarly low at 112 nM (Figure 4.5). This
supports that the porphyrin is properly seated and not in a position to influence
binding of the fatty acid. The high-spin transition also shows an alteration in the
Q-bands which are similar to PPolet with a blue-shift of 10 nm. This may infer
that lowering the potential increases the stability of the water ligand attached to
the Fe-MPIX, leading to difficulty in transitioning to a high-spin state. Association
have been reported between enzymes with lower potential and the accumulation
of high-spin, notably forming a decreased amount of high-spin with respect to the
decrease in potential 54, 55.
The hemochromagen assay shows no significant amount of Fe-PPIX
present in the folded protein (Figure 4.6). The Q-bands show a small peak at
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522 nm with a larger peak at 566 nm for PPolet, whereas there is a splitting of
two peaks at 506 and 518 nm with a larger peak at 546 nm. The reason for the
splitting of the β-band is unclear, but the 20 nm difference for the α-band may be
due to the loss of the thiol ligand after treatment with pyridine. In addition, the
absorbance ratios for the proteins as-purified (A 408/280 ≈ 1.0 for MPolet and
A 418/280 ≈ 1.2 for PPolet) are equivalent, indicating that there is little, if any, nonFe-MPIX bound enzyme in solution. This also confirms that there were no issues
concerning bacterial uptake of the porphyrin or difficulty with incorporation of the
non-native porphyrin into the enzyme. The distinct separation between the α and
β Q-bands also assist in confirming the absence of Fe-PPIX, since a mixture
would likely merge the bands into a single signal rather than two distinct features.
To ensure the protein folded correctly and confirm that the reduction of the vinyl
groups did not interfere with seating in the enzyme active site, spectra were
taken using Circular Dichroism which displayed no significant differences
between PPolet and MPolet (Figure 4.7).
Identification of intermediate species for Meso-Olet
The addition of a 300-fold excess of hydrogen peroxide led to the
formation of a ferryl-oxo Soret for Compound I at 357 nm and the formation of a
π-cation radical at 685 nm, the latter observed to blue-shift by 5 nm instead of
the 10 nm observed in every other peak (Figure 4.8). The origin of the π-cation
radical may be from a transition between the π-orbital and the cationic σ-orbital,
so the wavelength shift is not comparable to the ππ* transitions present in the
other peaks 56. The lack of an Fe-PPIX absorbance band in the hemochromagen
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spectrum shows that the total formation of the Cpd. I intermediate is from MPolet,
so no contributions needed to be subtracted out. The kinetic isotope effect (KIE)
of K H /K D in the presence of eicosanoic acid gives a value of ~18, which is higher
compared to other P450 enzymes and PP Olet, whose KIE is 8.1 with C20 fatty
acid 30, CYP101A1 = 3.8 with norcamphor 57, and HRP B-C = 10.1 with Nmethylaniline 58. The high KIE concludes that the hydrogen abstraction step is
the rate-limiting step in the reaction of MPolet with fatty acid. A plot of Cpd. I
decay in MPolet from the first kinetic rate measured at 428 nm at different
concentrations of hydrogen peroxide gives a dissociation constant for hydrogen
peroxide of 70 µM, a similar value found for PPolet (Figure 4.9). The absence of
significant differences conclude that the sidechains involved with stabilizing the
hydrogen peroxide (H85 and R245) are not displaces and are still within a
reasonable distance to the distal oxygen of the peroxide for an interaction to
occur.
The total accumulation of Cpd. I is greater with MPolet than PPolet,
indicating a difference between the two proteins in the activation energy (E a ) of
this intermediate. This is verified through Arrhenius measurements, which gives
an E a =15 kcal/mol for MPolet, around twice the energetic barrier of 7 kcal/mol
present in PPolet (Figure 4.10). Both of these barriers are high compared to
HRP, which has a calculated E a =3.5 kcal/mol 59 but the values match CYP119
bound with benzyl alcohol, which has an E a =15.1 kcal/mol 60. Interestingly, the
total accumulation of Cpd. I at 1 ms is about the same at both 4oC and 23oC,
indicating the presence of a highly stable Cpd. I intermediate. All rates and
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fittings are present in Figure 4.11 and Table 4.1 below and applies for all rate
data shown hereafter for MPolet and PPolet. In addition, the rate of Cpd I decay
for MPolet is 30 s-1, about 2.5x slower than PPolet at 75 s-1. These Cpd. I decay
rates are quicker than the rate of 9 s-1 calculated by Rittle for CYP119 31 or 29.4
s-1 calculated by Kellner for CYP119 61. The presence of the thiolate ligand does
make the intermediate react quicker than the more catalytically stable
Hemoglobin I, which has a rate of 0.03 s-1 62. These data conclude that MPolet
has a more stable Cpd I intermediate than PPolet.
The decay of Cpd. I coincides with the formation of the Cpd. II
intermediate. The Soret is centered at 422 nm and appears as a shoulder to the
low-spin form of the enzyme but has smaller absorbance due to a lower
extinction coefficient compared to the ferric, low-spin species. The appearance
of the Q-bands is similar to the low-spin form of the enzyme while the
hyperporphyrin absorbance increases at 350 nm. The decay of the Cpd. II
species back to low-spin is equivalent to, although slightly faster than, the rate of
PP Olet Cpd. II decay of 10 s-1. This rate is quicker than myeloperoxidase Cpd. II
decay, which has a rate of 0.0008 s-1 63, but there are not many examples of
Cpd. II accumulation, much less decay rates back to the ferric state. However,
Meso-Olet has a slightly lower E a for the formation of Compound II, resting at 15
kcal/mol instead of 18 kcal/mol. The combination of the rate of Cpd. II decay and
the lower activation energy gives an explanation for the increased quantity of
hydroxylated fatty acid present for fatty acid chain lengths < 18.
Turnover of Meso-Olet with variable chain length fatty acids
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All reported turnover data are present in Table 4.2 below, with
contributions for all PPolet data from Jose Amaya and Cooper Rutland. The
percent product conversion for MPolet is around 20% lower than with PPolet,
possibly due to the higher energy barrier for hydrogen abstraction from the
substrate. A similar dip in product conversions were observed with the
conversion of arginine to citrulline by MP NOS , which also showed a decrease of
14% in product distribution 17. However, both MPolet and PPolet show exclusive
conversion of eicosanoic acid to C19 alkene and carbon dioxide, inferring that
the amount of alkene observed is greater than 99% for C18 and higher for both
MPolet and PPolet. This exclusive creation of alkene for C20 fatty acid is also
observed for a variety of mutants 64 and homologs, specifically P450staph (data
not shown). As the chain length of the fatty acid shortens below C18, the amount
of alkene produced decreases, compensated by an increase in the production of
hydroxylated fatty acid. MPolet produces primarily β-OH fatty acid followed by γOH and finally α-OH products. This partially mimics the product preferences for
PPolet, as β-OH is the primary hydroxylated product followed by α-OH, although
previously published work did not indicate the presence of γ-OH fatty acid 64. For
all fatty acid chain lengths, there were no observable products outside of the
alkene and three hydroxylated products for the MPolet construct. It is currently
unclear why this change in product distribution occurred, given that alteration of
the porphyrin should not interfere with the binding behavior of the fatty acid or the
activation/orientation of the hydrogen peroxide oxidant.
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4.4 DISCUSSION
The potential use of PPolet as a biosynthetic catalyst for the creation of
alkene-based biofuels has been studied for several years. One deviation from
ongoing research that has not garnered much attention is determining how much
of an effect the electronics of the porphyrin itself regulate the product distribution
of the enzyme, with a primary reason stemming from the difficulty of
incorporating non-native porphyrins into the protein scaffold. This traditionally
was accomplished by growing the culture under a strictly anaerobic environment
with RP523 cells, which allowed the passage of non-native porphyrins and
contains a knockout for native porphyrin production. Attempts to express protein
in this cell line yielded low pellet weight due to excess cell death, presumably
from oxygen leakage during protein expression. However, the use of ChuA
provides a cheap and facile alternative for the incorporation of porphyrins while
growing the culture aerobically.
Fe-MPIX has a redox potential that is about mV lower than Fe-PPIX due
to the absence of additional resonance stabilization provided by the vinyl groups
into the porphyrin ring. This leads to a hypsochromic shift in the ππ*
absorbance bands by 10 nm. However, the activation of hydrogen peroxide is
not affected, with the K D and K off rates are similar to PPolet. Reports describing
MPIX substitution in monooxygenase enzymes show changes in the K D of
molecular oxygen. For instance, substitution of Fe-MPIX into CYP101A1 led to
an increase in the rate of autoxidation 65, but there is no evidence this applies to
peroxide activation.
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The formation of Cpd. I with MPolet is likely accompanied by a decrease
in basicity and increased difficulty for the ferryl-oxo to proceed with the hydrogen
abstraction from the substrate.

The addition of deuterated substrate and

excess hydrogen peroxide leads to equivalent accumulations of Cpd. I observed
at 2oC as 23oC, but the reasons for this stability are unknown. One explanation
may lie in the Arrhenius value for the E a for decay to Cpd. II being 12 kcal/mol for
MPolet, a higher value than 7.2 kcal/mol for PPolet. The higher temperature
would allow the Cpd. I intermediate to be more stable at higher temperatures for
MPolet. Also, the total conversion of fatty acid to product is lower than with
PPolet, possibly due to this longer lifespan of the Cpd. I intermediate at 25oC.
This subsequently increases the amount of time that substrate or product is in
the active site. In addition, studies of the kinetic isotope effects show that MPolet
has a KIE (k H /k D ) ≈ 18 compared to a KIE of ~7 observed in PPolet. Both values
are suggestive that the method of hydrogen abstraction mechanistically lies in an
electron tunneling event rather than a traditional proton transfer. However,
tunneling cannot overcome the decrease in the redox potential of the system and
this corresponds to a longer-lived Cpd. I.
Although the rate of Cpd. I decay for Cpd. I is higher in MPolet than it is for
PPolet, the rate of decay for Cpd. II back to ferric, low-spin is similar, with MPolet
exhibiting a rate of 15 kcal/mol compared to 18 kcal/mol for PPolet. This is
reflected by the lower ratio of alkene to hydroxylated product observed during
turnover experiments, as the rebound efficiency would increase slightly.
However, there does not be a rearrangement of hydroxylated products with
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MPolet, with the dictation of ratios showing a greater percentage of β-OH
products followed by γ-OH and α-OH. Since the position of hydroxylation should
not be determined by the porphyrin but rather by the residues in the distal pocket,
this infers the porphyrin is not improperly seated and does not lead to a shift in
the binding motif of any fatty acid substrates.
The enzyme allows the entry of MPIX, but rejects the incorporation of
diformyl-deuteroporphyrin IX (df-DPIX). According to the structural analysis of
PPolet from a published structure of the protein (PDBID #4L54), multiple
phenylalanine residues on the protein scaffold are positioned in a manner to
reject the transformation of the vinyl group at the 4 position into a polar functional
group, as this would prevent the porphyrin from seating correctly. However,
reduction of a 2,4-divinyl protoporphyrin to a 2,4-diethyl protoporphyrin has no
deleterious effect on its incorporation into the protein in vivo. This reinforces the
importance of the local environment when choosing specific porphyrin derivatives
to introduce into the active site of a P450, although porphyrins with polar
substituents at the 2,4 positions have been successfully implemented into
histidine-ligated proteins, such as myoglobin 9 and HRP 47.

4.5 CONCLUSION
Attempts to form alternative products for P450olet conclude that methods
must move beyond tuning the electronics of the porphyrin. The shift in the redox
potential for MPolet creates a greater amount of hydroxylated product, but there
are no observable changes upon reduction of the two vinyl groups, with all
possible products similar to PPolet. The sole product in the presence of
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eicosanoic acid is the C19 alkene while the percent turnover of fatty acid for all
chain lengths is lower than with PPolet, possibly due to the prolonged stability of
Cpd. I observable at room temperature, leading to longer time to perform a single
turnover.
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Figures and Tables

Figure 4.1: Structures of mesoporphyrin IX, protoporphyrin IX, and
diformyldeuteroporphyrin IX. Note the aldehyde placements on the diformyldeuteroporphyrin, which is repelled by the hydrophobic environment of the
protein around that 4 position.

Figure 4.2: 12% SDS-PAGE gel of pure P450olet after dfDPIX, MPIX,
and PPIX incorporation. The proteins are pure and express well, but the 2,4
diformylPPolet is a mixture of apo and Fe-PPIX bound.
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Figure 4.3: Optical characterization of PPolet. The spectra show the
ferric, low-spin (black), ferric, high-spin (green), ferrous (red), and ferrous-CO
complex (cyan).

Figure 4.4: Optical characterization of MPolet. The spectra show the
ferric, low-spin (black), ferric, high-spin (green), ferrous (red), and ferrous-CO
complex (cyan).
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Figure 4.5: Determination of K D using the optical changes at 417 nm and
396 nm for MPolet. 5 µM ferric, low-spin MPolet was mixed with eicosanoic acid
at 1 µM intervals. Fitting the plot with the Morrison equation gives a dissociation
constant of 112 nm, similar to the K D of PPolet.

Figure 4.6: Pyridine hemochromagen assay of MPolet and PPolet. The
absence of signal at 565 nm for MPolet is an indication there are negligible
quantities of Fe-PPIX present in the sample.
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Figure 4.7: CD spectra of purified MPolet and PPolet. This verifies that
there is no change in the secondary structure of the construct after incorporation
of a non-native porphyrin. The lower absorbance for MPolet is due to the
instability of P450olet in the given buffer and disproportionate crashing out
between MPolet and PPolet.

Figure 4.8: Stopped-flow spectra of 10 µM MPolet rapidly mixed against
10 mM hydrogen peroxide. This plot shows the conversion from Cpd. I (red
spectrum) to ferric, low-spin (black spectrum) over 1 second with 5 µM MPolet in
the presence of 5 mM hydrogen peroxide. Note the presence of the feature at
685 nm indicative of the π-cation of Cpd. I.
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Figure 4.9: Plot of Cpd. I decay as a function of hydrogen peroxide
concentration. The initial kinetic rate measured at 428 nm was utilized for this
plot at different concentrations of hydrogen peroxide. The slope is 358.2 s-1 and
the y-intercept is 25.1 mM-1 s-1. The dissociation constant of hydrogen peroxide
is 70 µM.

Figure 4.10: Arrhenius plot for Cpd. I and Cpd. II decay. The data was
collected at temperature points from 2oC-23oC at 3oC intervals. The activation
energy for the decay of Cpd. I (black) is 12 kcal/mol, a higher value than 7
kcal/mol for PPolet. The activation energy (E a ) for the decay of Cpd. II (red) is 15
kcal/mol, a similar value to PPolet. The pre-exponential A values are several
orders of magnitude higher than calculated for PPolet.
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Figure 4.11: Kinetic traces for intermediates formed with 5 µM MPolet
with 10 mM hydrogen peroxide. Time traces were taken over a one second timecourse and reflect the spectral changes shown in Figure 4.8. Black lines are the
collected data and the red lines are the fitting. The residuals are placed below
their respective traces. The top left shows the decay of Cpd. I and recorded at its
Soret at 360 nm. The top right shows overall formation of ferric, low-spin
measured at its Soret at 410 nm. The bottom left shows the formation and decay
of Cpd. II measured at 428 nm. The bottom right shows the decay of Cpd. I
measured at the π-cation feature at 685 nm.
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Table 4.1: Kinetic rates associated with PPolet and MPolet for Cpd. I
decay and Cpd. II decay.

....... The PPolet wavelengths and rates are shown in blue and are provided from
Jose Amaya and Cooper Rutland. The MPolet wavelengths and rates are shown
in red.

Table 4.2: Turnover data for MPolet and PPolet

MPolet data is derived from this work and data from PPolet is from Amaya
and Rutland. Note the lower total conversion for MPolet and the presence of
more hydroxylated product for the lower chain lengths.
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